RESULT_COUNT: 356,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
NBIX,NBIX:UW,BBG000GJTN99,Implied FXH Analyst Target Price: $74,2017-10-19 13:48:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x3STbBL1Cxo/implied-fxh-analyst-target-price-74-cm861822,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-10-18 12:04:08 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120408020.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,How Is Neurocrine Biosciences Positioned Now?,2017-10-16 17:23:14 +0000,http://finance.yahoo.com/r/88e6281c-c5ef-38dd-b177-f5d680f2cc9f/how-is-neurocrine-biosciences-positioned-now?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million."
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-10-16 13:43:19 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120522991.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-10-13 12:04:59 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120459595.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-10-12 12:05:09 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120509990.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-10-10 12:05:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120512921.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-10-06 12:05:23 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120523889.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,UPDATED: Neurocrine stock up 3% on higher-dose approval of tardive dyskinesia drug,2017-10-05 13:18:38 +0000,http://finance.yahoo.com/r/475e7e78-7546-3e1e-b9d6-67beea1fe9c9/Story.aspx?guid=A9674B80-C3BE-4518-84E1-6BD3F13C9662&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Neurocrine Biosciences Inc. shares rose 3% in premarket trade Thursday after the company said the Food and Drug Administration has approved a higher, 80 mg dose of its tardive dyskinesia drug. The 80 mg ..."
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-10-05 12:05:15 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120515920.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD),2017-10-05 11:00:00 +0000,https://finance.yahoo.com/news/neurocrine-announces-fda-approval-80-110000740.html?.tsrc=rss,"SAN DIEGO, Oct. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA® (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (TD).  INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which was approved by the FDA April 11, 2017, is the first FDA-approved product indicated for the treatment of adults with TD.  ""INGREZZA continues to be the TD treatment of choice,"" said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Approval Of 80 Mg Capsule Of INGREZZA - Quick Facts,2017-10-05 07:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uyi3IkJwMWI/neurocrine-announces-fda-approval-of-80-mg-capsule-of-ingrezza--quick-facts-20171005-00308,Neurocrine Announces FDA Approval Of 80 Mg Capsule Of INGREZZA - Quick Facts
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-09-25 12:02:36 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120236169.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-09-22 12:02:53 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120253891.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals,2017-09-22 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000468.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 22, 2017 / Shares of Neurocrine saw a pop on Thursday after a Baird analyst reiterated an ""outperform"" rating on the stock. Shares of BioCryst also saw gains ..."
NBIX,NBIX:UW,BBG000GJTN99,Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 91,2017-09-22 07:00:00 +0000,http://finance.yahoo.com/r/34f63d79-c5b3-30e3-b102-28e09c809d1a/stocks-to-watch-neurocrine-biosciences-sees-relative-strength-rating-jump-to-91?src=A00220&yptr=yahoo&.tsrc=rss,"Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating."
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-09-18 12:03:36 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120336095.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress,2017-09-15 13:25:00 +0000,https://finance.yahoo.com/news/neurocrine-announces-data-real-world-132500954.html?.tsrc=rss,"SAN DIEGO, Sept. 15, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) announced today upcoming poster presentations at the 2017 Annual Psych Congress featuring data from the RE-KINECT study outlining the real-world presence and impact of tardive dyskinesia (TD) on the lives of both patients and caregivers.  ""This year's Psych Congress serves as an excellent opportunity to dive deeper into the patient impact of TD, including demographics and healthcare utilization.  The RE-KINECT study provides valuable insight into the complexities and needs of these patients and how INGREZZA can address the movements that may disrupt patient lives,"" said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine."
NBIX,NBIX:UW,BBG000GJTN99,EQAL's Underlying Holdings Imply 10% Gain Potential,2017-09-12 13:38:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LomP70jkhYI/eqals-underlying-holdings-imply-10-gain-potential-cm844161,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-09-12 12:04:39 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120346095.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-09-11 12:04:50 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120450173.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference,2017-09-06 18:00:00 +0000,https://finance.yahoo.com/news/neurocrine-biosciences-present-morgan-stanley-180000763.html?.tsrc=rss,"Live Audio Webcast Will be on September 11, 2017 SAN DIEGO , Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, ..."
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain,2017-09-06 12:01:00 +0000,https://finance.yahoo.com/news/abbvie-submits-drug-application-u-120100546.html?.tsrc=rss,"- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful ..."
NBIX,NBIX:UW,BBG000GJTN99,Behind Bioverativ’s Analyst Recommendations This September,2017-09-06 11:37:49 +0000,http://finance.yahoo.com/r/06c943b4-ba2f-31ed-8397-34d58f7e0de5/behind-bioverativs-analyst-recommendations-this-september?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a ""hold."""
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Submits NDA To FDA For Investigational Oral Treatment Elagolix,2017-09-06 08:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YmBjBP-xspw/abbvie-submits-nda-to-fda-for-investigational-oral-treatment-elagolix-20170906-00583,AbbVie Submits NDA To FDA For Investigational Oral Treatment Elagolix
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-09-02 12:08:30 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120830187.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-09-01 12:03:46 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120346766.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference,2017-08-30 17:00:00 +0000,https://finance.yahoo.com/news/neurocrine-biosciences-present-baird-2017-170000862.html?.tsrc=rss,"Live Audio Webcast Will be on September 6, 2017 SAN DIEGO , Aug. 30, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, ..."
NBIX,NBIX:UW,BBG000GJTN99,Interesting NBIX Put And Call Options For October 20th,2017-08-30 15:51:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1wQYb7-8DYw/interesting-nbix-put-and-call-options-for-october-20th-cm839160,Investors in Neurocrine Biosciences Inc Symbol NBIX saw new options begin trading this week for the October 20th expiration At Stock Options Channel our YieldBoost formula has looked up and down the NBIX options chain for the new October 20th contracts and identified one put and one
NBIX,NBIX:UW,BBG000GJTN99,Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 82,2017-08-30 07:00:00 +0000,http://finance.yahoo.com/r/4889ed85-8973-338d-ae13-704b21f9ad3f/stocks-to-watch-neurocrine-biosciences-sees-relative-strength-rating-jump-to-82?src=A00220&yptr=yahoo&.tsrc=rss,"Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82."
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-29 12:03:37 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120340218.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-28 12:03:38 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120346988.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-25 12:01:57 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120157164.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,"Today's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.",2017-08-25 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000770.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 25, 2017 / U.S. markets closed in the red Thursday as investors await comments on monetary policy from the annual meeting of central bankers in Jackson Hole, Wyoming. ..."
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-24 12:04:31 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120206322.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-23 12:04:31 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120431077.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-21 12:02:10 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120210602.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-18 12:03:59 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120344673.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.,2017-08-14 12:03:46 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120346352.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT,2017-08-13 01:50:54 +0000,https://finance.yahoo.com/news/edited-transcript-nbix-earnings-conference-052942171.html?.tsrc=rss,Q1 2017 Neurocrine Biosciences Inc Earnings Call
NBIX,NBIX:UW,BBG000GJTN99,Edited Transcript of NBIX earnings conference call or presentation 3-Aug-17 9:00pm GMT,2017-08-12 05:15:44 +0000,https://finance.yahoo.com/news/edited-transcript-nbix-earnings-conference-230807237.html?.tsrc=rss,Q2 2017 Neurocrine Biosciences Inc Earnings Call
NBIX,NBIX:UW,BBG000GJTN99,"IHS Markit Score downgrades Neurocrine Biosciences Inc to 12 out of 100, ranking negatively in two out of three available IHS Markit categories.",2017-08-11 12:04:14 +0000,https://finance.yahoo.com/news/ihs-markit-score-downgrades-neurocrine-120414930.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,"IHS Markit Score upgrades Neurocrine Biosciences Inc to 34 out of 100, despite ranking positively in only one IHS Markit category.",2017-08-10 12:04:22 +0000,https://finance.yahoo.com/news/ihs-markit-score-upgrades-neurocrine-120422110.html?.tsrc=rss,Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
NBIX,NBIX:UW,BBG000GJTN99,Featured Company News - Mylan Launches Avonza(TM) in India,2017-08-10 11:10:00 +0000,https://finance.yahoo.com/news/featured-company-news-mylan-launches-111000181.html?.tsrc=rss,"Research Desk Line-up: Neurocrine Biosciences Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 10, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ..."
NBIX,NBIX:UW,BBG000GJTN99,Analysts See 10% Upside For IYH,2017-08-09 14:37:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yiCgdanYpbE/analysts-see-10-upside-for-iyh-cm829354,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
NBIX,NBIX:UW,BBG000GJTN99,Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Sage Therapeutics,2017-08-07 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000505.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 7, 2017 / Despite a wider net loss in the second quarter than compared to a year ago, shares of Neurocrine still closed up nearly 10% on Friday after reporting impressive ..."
NBIX,NBIX:UW,BBG000GJTN99,NBIX: Strong Start to INGREZZA® Launch,2017-08-04 17:00:00 +0000,https://finance.yahoo.com/news/nbix-strong-start-ingrezza-launch-170000536.html?.tsrc=rss,"On August 3, 2017, Neurocrine Biosciences, Inc. (NBIX) announced financial results for the second quarter of 2017.  The company reported $6.3 million in revenue from the sale of INGREZZA®, which was officially launched on May 1, 2017 following its approval by the U.S. Food and Drug Administration (FDA) in April 2017.  In support of this, during the conference call to discuss the quarterly results, management indicated that the pharmacies keep less than 1 week of INGREZZA® in inventory."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 2Q loss,2017-08-03 21:41:17 +0000,https://finance.yahoo.com/news/neurocrine-reports-2q-loss-214117557.html?.tsrc=rss,The San Diego-based company said it had a loss of 68 cents per share. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for ...
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports Second Quarter 2017 Results,2017-08-03 20:01:00 +0000,https://finance.yahoo.com/news/neurocrine-biosciences-reports-second-quarter-200100674.html?.tsrc=rss,- INGREZZA® Net Product Sales of $6.3 Million in Initial Two Months of Commercialization as the First and Only U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia ...
NBIX,NBIX:UW,BBG000GJTN99,"Investor Network: Neurocrine Biosciences, Inc. to Host Earnings Call",2017-08-03 18:20:00 +0000,https://finance.yahoo.com/news/investor-network-neurocrine-biosciences-inc-182000189.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 03, 2017 at 5:00 ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results,2017-07-28 17:00:00 +0000,https://finance.yahoo.com/news/neurocrine-biosciences-announces-conference-call-170000399.html?.tsrc=rss,"Conference Call and Webcast Scheduled for August 3, 2017 SAN DIEGO , July 28, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report second quarter ..."
NBIX,NBIX:UW,BBG000GJTN99,"Today's Research Reports on Stocks to Watch: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals",2017-07-25 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000228.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Shares of Neurocrine Biosciences saw a jump in price yesterday, retracing from a loss this past Friday. The company announced a new executive to its management ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer,2017-07-21 13:28:00 +0000,https://finance.yahoo.com/news/neurocrine-biosciences-announces-appointment-julie-132800092.html?.tsrc=rss,"""Neurocrine is delighted to welcome Julie Cooke as our Chief People Officer to lead our Human Resource function,"" said David-Alexandre C. Gros, President and Chief Operating Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIX,2017-07-12 16:46:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-uGGR9SYjYQ/neurocrine-biosciences-breaks-above-200-day-moving-average-bullish-for-nbix-cm815074,In trading on Wednesday shares of Neurocrine Biosciences Inc Symbol NBIX crossed above their 200 day moving average of 45 78 changing hands as high as 46 28 per share Neurocrine Biosciences Inc shares are currently trading up about 1 5 on the day The chart below shows the one
NBIX,NBIX:UW,BBG000GJTN99,Why Neurocrine is charging twice as much for its new drug as it said it would,2017-07-05 12:26:39 +0000,http://finance.yahoo.com/r/1d0b0880-84fa-3a69-ac99-c91288fd1b90/Story.aspx?guid=733CE0E4-2E9B-11E7-9368-82EFAFBCD0A4&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Patients on the recommended dose will pay double — about $5,300 more a month."
NBIX,NBIX:UW,BBG000GJTN99,Bayer Starts Phase III Study for Uterine Fibroids' Candidate,2017-07-04 14:45:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fh9A1RDetl0/bayer-starts-phase-iii-study-for-uterine-fibroids-candidate-cm811556,Bayer Aktiengesellschaft BAYRY announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids Bayer s share price shows that the company has outperformed the Zacks classified Large Cap
NBIX,NBIX:UW,BBG000GJTN99,Bayer Starts Phase III Study for Uterine Fibroids&apos; Candidate,2017-07-04 12:25:12 +0000,https://finance.yahoo.com/news/bayer-starts-phase-iii-study-122512422.html?.tsrc=rss,Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences: Ingrezza, Collaborations, Ratings",2017-07-03 13:01:04 +0000,http://finance.yahoo.com/r/7047c32e-7a2e-3545-a0be-72d5f6fe3997/neurocrine-biosciences-ingrezza-collaborations-ratings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIX,2017-06-20 17:23:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/om1ehMoneOM/neurocrine-biosciences-breaks-above-200-day-moving-average-bullish-for-nbix-cm805776,In trading on Tuesday shares of Neurocrine Biosciences Inc Symbol NBIX crossed above their 200 day moving average of 46 18 changing hands as high as 46 64 per share Neurocrine Biosciences Inc shares are currently trading up about 2 6 on the day The chart below shows the one
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference,2017-06-09 17:00:00 +0000,https://finance.yahoo.com/news/neurocrine-biosciences-present-goldman-sachs-170000589.html?.tsrc=rss,"SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38 th Annual ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences To Present At Jefferies Conference; Webcast At 1:30 PM ET,2017-06-08 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BmVWvJ8oqkQ/neurocrine-biosciences-to-present-at-jefferies-conference-webcast-at-130-pm-et-20170608-00899,Neurocrine Biosciences To Present At Jefferies Conference; Webcast At 1:30 PM ET
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders,2017-06-02 13:25:00 +0000,https://finance.yahoo.com/news/neurocrine-announces-presentations-related-ingrezza-132500973.html?.tsrc=rss,"The 21st International Congress of Parkinson's Disease and Movement Disorders will take place in Vancouver BC, Canada from June 4-8, 2017.  In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference,2017-06-01 20:18:00 +0000,https://finance.yahoo.com/news/neurocrine-biosciences-present-jefferies-2017-201800639.html?.tsrc=rss,"SAN DIEGO, June 1, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2017 Global Healthcare ..."
NBIX,NBIX:UW,BBG000GJTN99,"Top Losers in the Healthcare Sector: May 22–26, 2017",2017-05-31 16:01:33 +0000,http://finance.yahoo.com/r/547c1ea6-b28f-3436-b92c-632256284434/top-losers-in-the-healthcare-sector-may-22-26-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"During the week ended May 26, 2017, Alexion Pharmaceuticals (ALXN) saw the biggest loss in the healthcare sector. ALXN's stock price witnessed a steep fall of ~14.2%."
NBIX,NBIX:UW,BBG000GJTN99,Biotech Musical Chairs: Who Leads Next,2017-05-31 10:00:00 +0000,http://finance.yahoo.com/r/798fae83-dc19-360c-a154-7db0f1650f11/biotech-musical-chairs-who-leads-next-ibb-nbix?partner=YahooSA&yptr=yahoo&.tsrc=rss,The biotech sector as measured by the iShares Nasdaq Biotech ETF is down another 1.40% today.
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Becomes Oversold (NBIX),2017-05-30 17:35:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CWXtg6khBkE/neurocrine-biosciences-becomes-oversold-nbix-cm796338,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
NBIX,NBIX:UW,BBG000GJTN99,The Math Shows IYH Can Go To $175,2017-05-30 14:31:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LWhe8PztuBE/the-math-shows-iyh-can-go-to-175-cm796082,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
NBIX,NBIX:UW,BBG000GJTN99,NBIX: P2 Study in Tourette’s Syndrome Does Not Meet Primary Endpoint; P2b Study to Start Before End of 2017,2017-05-25 15:30:00 +0000,https://finance.yahoo.com/news/nbix-p2-study-tourette-syndrome-153000679.html?.tsrc=rss,"The T-Force GREEN study was a Phase 2 study designed to evaluate the safety, tolerability, and efficacy of INGREZZA™ in children and adolescents with Tourette syndrome (TS) (NCT02679079).  It was a randomized, double blind, placebo controlled, multi-dose, parallel group trial of approximately 90 children and adolescents.  Patients received once-daily dosing of INGREZZA™ or placebo in a 1:1:1 fashion during a six-week treatment period."
NBIX,NBIX:UW,BBG000GJTN99,Biotech And Pharma Industry And Stock News,2017-05-25 12:43:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
NBIX,NBIX:UW,BBG000GJTN99,"Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX...",2017-05-24 21:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fKol1YRRM_4/gainers--losers-of-may-24-pbyi-ino-nvcr-akao-nbix-20170524-01409,"Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX..."
NBIX,NBIX:UW,BBG000GJTN99,"Health Care Sector Update for 05/24/2017: PBYI,INO,NBIX",2017-05-24 20:30:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TgB-UFQG_4E/health-care-sector-update-for-05242017-pbyiinonbix-cm794177,Top Health Care StocksTop Health Care Stocks JNJ 0 01 JNJ 0 01 PFE 0 14 PFE 0 14 ABT 0 37 ABT 0 37 MRK 0 77 MRK 0 77 AMGN 0 32 AMGN 0 32 Health care stocks were in the middle of Wednesday s leaderboard this afternoon with the NYSE Health Care Index climbing over 0 3 while shares
NBIX,NBIX:UW,BBG000GJTN99,Did Neurocrine Just Leave The Door Open For Teva In Tourette&apos;s?,2017-05-24 20:21:00 +0000,http://finance.yahoo.com/r/547aef74-c4c9-3315-8f47-418c27885737/did-neurocrine-just-leave-the-door-open-for-teva-in-tourettes?src=A00220&yptr=yahoo&.tsrc=rss,"Neurocrine may have left the door open for Teva to get an early lead in Tourette&apos;s syndrome, an analyst said Wednesday."
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out",2017-05-24 19:34:28 +0000,https://finance.yahoo.com/news/neurocrines-phase-2-disappointment-why-193428474.html?.tsrc=rss,"Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug . The company announced ..."
NBIX,NBIX:UW,BBG000GJTN99,"Health Care Sector Update for 05/24/2017: SBPH,INO,NBIX",2017-05-24 18:49:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nc7lWH61P7s/health-care-sector-update-for-05242017-sbphinonbix-cm794092,Top Health Care StocksTop Health Care Stocks JNJ 0 01 JNJ 0 01 PFE 0 14 PFE 0 14 ABT 0 37 ABT 0 37 MRK 0 77 MRK 0 77 AMGN 0 32 AMGN 0 32 Health care stocks were drifting farther down Wednesday s leaderboard this afternoon with the NYSE Health Care Index climbing more than 0 3
NBIX,NBIX:UW,BBG000GJTN99,Industry News And Stocks To Watch,2017-05-24 18:30:38 +0000,http://finance.yahoo.com/r/967e6bbb-f7b7-35a3-a9fe-d7b3be3ea79e/industry-news-and-stocks-to-watch?src=A00220&yptr=yahoo&.tsrc=rss,"Track the latest news and stocks to watch across the tech, retail, finance and other industries."
NBIX,NBIX:UW,BBG000GJTN99,"Biotech Movers: Inovio, Neurocrine, Alnylam",2017-05-24 13:29:00 +0000,http://finance.yahoo.com/r/1e338e4a-4ca6-325e-bb8d-69848a2b10e3/biotech-movers-inovio-neurocrine-alnylam.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday."
NBIX,NBIX:UW,BBG000GJTN99,"MRK's Keytruda Scores Another FDA Nod, NBIX Disappoints, SBPH Achieves It",2017-05-24 01:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3h3f9Ahd2QE/mrks-keytruda-scores-another-fda-nod-nbix-disappoints-sbph-achieves-it-20170524-00023,"MRK's Keytruda Scores Another FDA Nod, NBIX Disappoints, SBPH Achieves It"
NBIX,NBIX:UW,BBG000GJTN99,Nuerocrine's Tourette's syndrome drug trial fails,2017-05-23 20:15:00 +0000,https://finance.yahoo.com/video/nuerocrines-tourettes-syndrome-drug-trial-201500231.html?.tsrc=rss,CNBC's Meg Tirrell reports Neurocrine's stock fell after hours following reports it's drug trial for a new Tourette's medication had failed.
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome,2017-05-23 20:01:00 +0000,https://finance.yahoo.com/news/neurocrine-announces-phase-ii-results-200100712.html?.tsrc=rss,"SAN DIEGO, May 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA®(valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint.  The pre-specified primary endpoint was the change-from-baseline between the placebo and active groups in the Yale Global Tic Severity Scale (YGTSS) at Week 6 in the intent-to-treat (ITT) population.  Exposure-response analysis showed that the selected doses for this placebo-controlled Phase II study were below the therapeutic range for adequate tic reduction in the majority of pediatric subjects."
NBIX,NBIX:UW,BBG000GJTN99,What Drug Approval Means for Neurocrine Biosciences,2017-05-20 13:11:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2b-RqJ1HtN4/what-drug-approval-means-for-neurocrine-biosciences-cm792255,Neurocrine Biosciences NBIX announced in April that the company s drug Ingrezza valbenazine has been approved by the U S Food and Drug Administration FDA for treating tardive dyskinesia TD a burdensome and often incurable form of dyskinesia The FDA granted this application
NBIX,NBIX:UW,BBG000GJTN99,What Drug Approval Means for Neurocrine Biosciences,2017-05-19 18:10:15 +0000,https://finance.yahoo.com/news/drug-approval-means-neurocrine-biosciences-181015082.html?.tsrc=rss,A secondary catalyst to watch this month
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting,2017-05-18 20:05:00 +0000,https://finance.yahoo.com/news/neurocrine-announces-ingrezza-valbenazine-capsules-200500033.html?.tsrc=rss,"""This year's annual meeting of the APA is an excellent opportunity to present additional data and analyses from the extensive clinical development program both supporting and differentiating INGREZZA,"" said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine."
NBIX,NBIX:UW,BBG000GJTN99,InPlay from Briefing.com,2017-05-17 16:56:30 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis,2017-05-17 16:00:00 +0000,https://finance.yahoo.com/news/abbvie-presents-pivotal-phase-3-160000294.html?.tsrc=rss,"NORTH CHICAGO, Ill., May 17, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data from ..."
NBIX,NBIX:UW,BBG000GJTN99,NBIX: INGREZZA™ Launch Commences…,2017-05-11 20:00:00 +0000,http://finance.yahoo.com/news/nbix-ingrezza-launch-commences-200000982.html?.tsrc=rss,"On May 9, 2017, Neurocrine Biosciences Inc. (NBIX) announced financial results for the first quarter of 2017 and provided a business update.  As expected, the company did not report any revenue during the first quarter of 2017, compared with a $15 million milestone that was paid by AbbVie during the first quarter of 2016."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference,2017-05-11 19:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-bank-america-190000014.html?.tsrc=rss,"SAN DIEGO, May 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch ..."
NBIX,NBIX:UW,BBG000GJTN99,Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT,2017-05-11 01:25:45 +0000,http://finance.yahoo.com/news/edited-transcript-nbix-earnings-conference-052942171.html?.tsrc=rss,Q1 2017 Neurocrine Biosciences Inc Earnings Call
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 1Q loss,2017-05-09 21:24:24 +0000,http://finance.yahoo.com/news/neurocrine-reports-1q-loss-212424263.html?.tsrc=rss,The San Diego-based company said it had a loss of 90 cents per share. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for ...
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports First Quarter 2017 Results,2017-05-09 20:01:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-reports-first-quarter-200100427.html?.tsrc=rss,"SAN DIEGO, May 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2017, highlighted by the launch of INGREZZA ® (valbenazine) ..."
NBIX,NBIX:UW,BBG000GJTN99,"Investor Network: Neurocrine Biosciences, Inc. to Host Earnings Call",2017-05-09 17:30:00 +0000,http://finance.yahoo.com/news/investor-network-neurocrine-biosciences-inc-173000022.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 5:00 PM Eastern Time. ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results,2017-05-03 17:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-announces-conference-call-170000848.html?.tsrc=rss,"SAN DIEGO, May 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report first quarter 2017 results after Nasdaq market close on Tuesday, May 9, 2017. ..."
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes",2017-05-02 21:04:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-inc-announces-closing-210400664.html?.tsrc=rss,"SAN DIEGO, May 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it has completed its previously announced private offering of $517.5 million aggregate principal amount of its 2.25% convertible senior notes due 2024 (the ""notes""), which includes $67.5 million aggregate principal amount of notes that were sold pursuant to the exercise of the initial purchasers' option to purchase additional notes.  The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act"").  The net proceeds from the offering, after deducting the initial purchasers' discounts and commissions and estimated offering expenses payable by Neurocrine, were approximately $502.2 million."
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected",2017-05-01 12:51:42 +0000,http://finance.yahoo.com/r/5570d0dd-4906-3f2c-81ad-15d349ba1d05/Story.aspx?guid=3DE44326-2AA7-11E7-85A0-6A869C5876AE&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about ..."
NBIX,NBIX:UW,BBG000GJTN99,The 3 Best Pharmaceutical Stocks to Buy in 2017,2017-04-29 21:26:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1x9pMmqVuJk/the-3-best-pharmaceutical-stocks-to-buy-in-2017-cm781694,One big benefit that comes from owning pharmaceutical stocks is that their products remain in demand even during periods of economic stress That allows drugmakers to crank out profits even when the economy catches a cold So what pharmaceutical stocks should investors buy this
NBIX,NBIX:UW,BBG000GJTN99,The 3 Best Pharmaceutical Stocks to Buy in 2017,2017-04-29 19:31:00 +0000,http://finance.yahoo.com/r/d001292e-7a4c-327e-9e5f-79cf6d2f8d2f/the-3-best-pharmaceutical-stocks-to-buy-in-2017.aspx?yptr=yahoo&.tsrc=rss,"Here&apos;s why Pfizer, Teligent, and Neurocrine Biosciences are all top pharmaceutical stocks to own this year."
NBIX,NBIX:UW,BBG000GJTN99,InPlay from Briefing.com,2017-04-26 22:50:47 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering",2017-04-26 22:48:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-inc-prices-450-224800861.html?.tsrc=rss,"The notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act"").  Neurocrine also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $67.5 million aggregate principal amount of notes.  The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable in cash semi-annually in arrears at a rate of 2.25% per annum."
NBIX,NBIX:UW,BBG000GJTN99,"Notable ETF Inflow Detected - XBI, VRTX, BIVV, NBIX",2017-04-26 16:03:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rk4xjwcSoew/notable-etf-inflow-detected-xbi-vrtx-bivv-nbix-cm779482,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 264 9 million dollar inflow that s a 8 9 increase week over week in outstanding
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Proposed Convertible Senior Notes Offering,2017-04-25 20:01:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-proposed-convertible-senior-200100976.html?.tsrc=rss,"SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the ""notes"") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act"").  The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable semiannually in arrears.  The notes will be convertible in certain circumstances into cash, shares of Neurocrine's common stock, or a combination of cash and shares of Neurocrine's common stock, at Neurocrine's election."
NBIX,NBIX:UW,BBG000GJTN99,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 17:44:54 +0000,http://finance.yahoo.com/news/mark-calendar-days-may-play-174454598.html?.tsrc=rss,"Investment in biotech stocks is fraught with risks. These stocks trade in anticipation of some ""make-or-break"" events called catalysts and therefore face the danger of seeing wild swings in the ..."
NBIX,NBIX:UW,BBG000GJTN99,Biotech Stocks Facing FDA Decision In May,2017-04-24 06:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m7nOglfsE90/biotech-stocks-facing-fda-decision-in-may-20170424-00222,Biotech Stocks Facing FDA Decision In May
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting,2017-04-21 10:00:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-ingrezza-long-term-100000496.html?.tsrc=rss,"SAN DIEGO, April 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia will be presented as a platform presentation at the American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 in Boston.  Additionally, two posters representing additional data from several clinical trials of INGREZZA will be presented, including an analysis of its pharmacologic characteristics.  ""We are very pleased to present additional robust data from the largest ever clinical program in tardive dyskinesia at this year's American Academy of Neurology Annual Meeting,"" said Chris O'Brien, M.D., FAAN, Chief Medical Officer at Neurocrine."
NBIX,NBIX:UW,BBG000GJTN99,Should You Make a Bet on the Healthcare Stocks?,2017-04-19 00:03:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f4rAQHcY-lU/should-you-make-a-bet-on-the-healthcare-stocks-cm775583,0 25 A Wide Focused Outlook On The Healthcare Market 3 45 Hidden Gems In the Healthcare Sector 6 40 Immunotherapy Robotic Surgery and Investment Ideas 14 00 Where To Invest In The Healthcare Market 19 10 Neurocrine
NBIX,NBIX:UW,BBG000GJTN99,Should You Make a Bet on the Healthcare Stocks?,2017-04-18 22:12:10 +0000,http://finance.yahoo.com/news/bet-healthcare-stocks-221210800.html?.tsrc=rss,The healthcare industry is much more than Obamacare and drug prices as many companies are using new technologies to create breakthroughs in medicine.
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug",2017-04-13 23:54:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PS7I00Rmc_w/neurocrines-stock-up-fda-nod-for-tardive-dyskinesia-drug-cm774133,Shares of Neurocrine Biosciences Inc NBIX soared 25 on Tuesday after announcing the FDA approval ofIngrezza valbenazine capsules a day before for the treatment of adults with tardive dyskinesia TD Ingrezza is the first and the only drug approved by the FDA for the treatment of adults
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine&apos;s Stock Up, FDA Nod for Tardive Dyskinesia Drug",2017-04-13 21:46:09 +0000,http://finance.yahoo.com/news/neurocrine-apos-stock-fda-nod-214609675.html?.tsrc=rss,"Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD)."
NBIX,NBIX:UW,BBG000GJTN99,Pharma companies are seeking a new treatment — for the backlash against high drug prices,2017-04-13 21:13:20 +0000,http://finance.yahoo.com/r/36f82db8-2ee5-3a70-a1a3-5493692ddc0c/Story.aspx?guid=5067E1B2-1F7E-11E7-8C49-7028AD27D08D&siteid=yhoof2&yptr=yahoo&.tsrc=rss,How much will Neurocrine Biosciences’ new treatment for a neurological disorder cost? The company won’t say yet.
NBIX,NBIX:UW,BBG000GJTN99,"Company News for April 13, 2017",2017-04-13 17:56:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/llPVbZ_QVvQ/company-news-for-april-13-2017-cm773947,160 Shares of BlackBerry Ltd BBRY advanced 16 after the company achieved success in an 814 9 million arbitration case against Qualcomm Inc QCOM 160 160 160 The Valspar Corp s VAL shares gained 1 after the company decided to sell industrial coatings business for 420
NBIX,NBIX:UW,BBG000GJTN99,"Company News for April 13, 2017",2017-04-13 15:17:03 +0000,http://finance.yahoo.com/news/company-news-april-13-2017-151703425.html?.tsrc=rss,"Companies in the News are: BBRY,QCOM,VAL,AXTA,NBIX,NAK"
NBIX,NBIX:UW,BBG000GJTN99,Blog Coverage Neurocrine Stock Price Rocketed 25% After FDA's First Ever Approval for its Drug for the Treatment of Tardive Dyskinesia,2017-04-13 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-neurocrine-stock-price-121500448.html?.tsrc=rss,"Upcoming AWS Coverage on SteadyMed Post-Earnings Results LONDON, UK / ACCESSWIRE / April 13, 2017 / Active Wall St. blog coverage looks at the headline from Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ..."
NBIX,NBIX:UW,BBG000GJTN99,"Gainers & Losers Of Apr.12: ADPT, NBIX, NOVN, PLX, ALBO...",2017-04-12 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-1kVXrsqjJU/gainers--losers-of-apr12-adpt-nbix-novn-plx-albo-20170412-01276,"Gainers & Losers Of Apr.12: ADPT, NBIX, NOVN, PLX, ALBO..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Avoids Suicide Warning In Teva-Rivaling Drug; Stock Pops,2017-04-12 20:54:00 +0000,http://finance.yahoo.com/r/b63f4b89-9204-3735-a7d5-546431d7c5e3/neurocrine-avoids-suicide-warning-in-teva-rivaling-drug-stock-pops?src=A00220A&yptr=yahoo&.tsrc=rss,"Neurocrine has a lead on Teva, grabbing FDA approval late Tuesday for the first drug in tardive dyskinesia."
NBIX,NBIX:UW,BBG000GJTN99,Here's Why Neurocrine (NBIX) Stock is Soaring 24% Today,2017-04-12 20:53:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PhXMgP1Sfeo/heres-why-neurocrine-nbix-stock-is-soaring-24-today-cm773459,Neurocrine Biosciences NBIX a San Diego based biotechnology company is soaring today on FDA approval of their drug INGREZZA valbenazine As of 1 40 PM EST Neurocrine is trading up 24 06 to 51 46 a share INGREZZA treats patients who suffer from tardive dyskinesia TD A
NBIX,NBIX:UW,BBG000GJTN99,Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder,2017-04-12 20:34:26 +0000,http://finance.yahoo.com/news/biotech-stock-neurocrine-surges-more-140523128.html?.tsrc=rss,"Neurocrine says the FDA has approved Ingrezza, the only drug for treatment of adults with tardive dyskinesia."
NBIX,NBIX:UW,BBG000GJTN99,"Health Care Sector Update for 04/12/2017: NBIX,ADPT,WVE",2017-04-12 20:14:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3SSIshR1H_E/health-care-sector-update-for-04122017-nbixadptwve-cm773478,Top Health Care StocksTop Health Care Stocks JNJ 0 91 JNJ 0 91 PFE 0 11 PFE 0 11 MRK 0 23 MRK 0 23 ABT 0 93 ABT 0 93 AMGN 0 02 AMGN 0 02 Health care stocks were edging higher in late trade reversing earlier declines with the NYSE Health Care Index climbing about 0 2 while
NBIX,NBIX:UW,BBG000GJTN99,"HP Hits 2-Year High On Upgrade; GrubHub, Neurocrine Touted",2017-04-12 20:11:18 +0000,http://finance.yahoo.com/r/41b71275-d611-32e5-92e9-ec89ba92cc46/hp-hits-2-year-high-on-upgrade-grubhub-neurocrine-touted?src=A00220A&yptr=yahoo&.tsrc=rss,"Analyst actions on Wednesday included upgrades for HP, GrubHub, Lululemon, and a price-target hike for Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,NBIX: INGREZZA™ Approved by the FDA,2017-04-12 19:00:00 +0000,http://finance.yahoo.com/news/nbix-ingrezza-approved-fda-190000259.html?.tsrc=rss,"On April 11, 2017, Neurocrine Biosciences, Inc. (NBIX) announced that the U.S. Food and Drug Administration (FDA) approved INGREZZA™ for the treatment of tardive dyskinesia (TD).  INGREZZA™ is the first medicine to be approved by the FDA for the treatment of TD, and is the culmination of over a decade of work since the compound was discovered in Neurocrine’s laboratory.  People with schizophrenia and other neuropsychiatric disorders are particularly vulnerable to developing TD after treatment with conventional neuroleptics, anticholinergics, substances of abuse, and other agents."
NBIX,NBIX:UW,BBG000GJTN99,"Wednesday's ETF Movers: FBT, XME",2017-04-12 18:54:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u-bxD2v07bc/wednesdays-etf-movers-fbt-xme-cm773414,In trading on Wednesday the First Trust NYSE Arca Biotechnology Index Fund ETF FBT is outperforming other ETFs up about 0 7 on the day Components of that ETF showing particular strength include shares of Neurocrine Biosciences NBIX up about 23 7 and shares of Grifols GRFS
NBIX,NBIX:UW,BBG000GJTN99,Here&apos;s Why Neurocrine (NBIX) Stock is Soaring 24% Today,2017-04-12 18:54:06 +0000,http://finance.yahoo.com/news/apos-why-neurocrine-nbix-stock-185406106.html?.tsrc=rss,"Neurocrine Biosciences (NBIX), a San Diego based biotechnology company, is soaring today on FDA approval of their drug INGREZZA (valbenazine)."
NBIX,NBIX:UW,BBG000GJTN99,Neurocine Biosciences gets FDA approval for new drug,2017-04-12 18:43:00 +0000,http://finance.yahoo.com/video/neurocine-biosciences-gets-fda-approval-184300069.html?.tsrc=rss,"CNBC's Meg Tirrell reports the latest in biotech news as Neurocine Biosciences receives FDA approval for their movement disorder drug, as well as Smithfield Foods setting up a bioscience unit with a potential for pig-to-human organ transplants."
NBIX,NBIX:UW,BBG000GJTN99,Why Neurocrine Biosciences Stock Is Soaring Higher Today,2017-04-12 17:55:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8cbob6Fh7sY/why-neurocrine-biosciences-stock-is-soaring-higher-today-cm773358,What happened Shares of the mid cap biotech Neurocrine Biosciences NASDAQ NBIX rocketed higher today as a result of the Food and Drug Administration FDA approving the company s first drug Ingrezza as a treatment for adults with tardive dyskinesia TD Tardive dyskinesia is
NBIX,NBIX:UW,BBG000GJTN99,"Delta Air Lines, Inc. Stock Is a Great Value Buy After Q1 Earnings (DAL)",2017-04-12 17:53:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VBoq8z85jWk/delta-air-lines-inc-stock-is-a-great-value-buy-after-q1-earnings-dal-cm773409,InvestorPlace Stock Market News Stock Advice amp Trading Tips Shares of Delta Air Lines Inc NYSE DAL are on the rise Wednesday morning climbing about 3 on a first quarter earnings report that topped the pros expectations It s not much but it s
NBIX,NBIX:UW,BBG000GJTN99,"Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva",2017-04-12 17:40:41 +0000,http://finance.yahoo.com/news/approval-neurocrines-ingrezza-no-surprise-174041057.html?.tsrc=rss,"Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) investors got a pleasant surprise when the FDA approved the company’s Ingrezza drug for treatment of tardive dyskinesia (TD). While the approval itself was ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside,2017-04-12 16:57:44 +0000,http://finance.yahoo.com/news/neurocrine-outperforms-even-bullish-estimates-165744778.html?.tsrc=rss,"Shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) soared by more than 20 percent Wednesday after the U.S. Food and Drug Administration granted approval for the company's Ingrezza therapy. Ingrezza ..."
NBIX,NBIX:UW,BBG000GJTN99,"3 Stocks to Watch on Wednesday: Tesla, Inc. (TSLA), Delta Air Lines, Inc. (DAL) and Neurocrine Biosciences, Inc. (NBIX)",2017-04-12 16:54:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HE0mfZmNt60/3-stocks-to-watch-on-wednesday-tesla-inc-tsla-delta-air-lines-inc-dal-and-neurocrine-biosciences-inc-nbix-cm773377,InvestorPlace Stock Market News Stock Advice amp Trading Tips Tuesday saw stocks dip slightly led by tech stocks which were among the worst performers with 0 4 losses as a group The 160 S amp P 500 fell 0 1 the 160 Dow Jones Industrial 160 Average
NBIX,NBIX:UW,BBG000GJTN99,"PulteGroup, Inc. (PHM) Stock Could Build Gains in a Hurry",2017-04-12 16:53:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y_2axTtkFEI/pultegroup-inc-phm-stock-could-build-gains-in-a-hurry-cm773361,InvestorPlace Stock Market News Stock Advice amp Trading Tips Shares of homebuilding stocks such as 160 PulteGroup Inc 160 NYSE PHM rallied on Tuesday April 11 and increasingly look ripe for another leg higher Technically speaking PHM stock has
NBIX,NBIX:UW,BBG000GJTN99,Why Neurocrine Biosciences Stock Is Soaring Higher Today,2017-04-12 16:43:46 +0000,http://finance.yahoo.com/r/d6eed183-a8b7-3714-a5a8-26fedffe9a32/why-neurocrine-biosciences-stock-is-soaring-higher.aspx?yptr=yahoo&.tsrc=rss,"The biotech struck regulatory gold with its tardive dyskinesia drug, Ingrezza."
NBIX,NBIX:UW,BBG000GJTN99,FDA Approves Neurocrine Biosciences Movement Disorder Therapy,2017-04-12 16:13:00 +0000,http://finance.yahoo.com/r/67eac8a6-8504-3c30-be1e-a39df1495bee/fda-approves-neurocrine-biosciences-movement-disorder-therapy?partner=YahooSA&yptr=yahoo&.tsrc=rss,Neurocrine Biosciences granted approval for facial movement disorder that affects half a million Americans.
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Wins Big With FDA Approval,2017-04-12 14:40:26 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-wins-big-fda-144026438.html?.tsrc=rss,Neurocrine Biosciences saw its shares jump after the company reported that the FDA had approved Ingrezza capsules for the treatment of adults with tardive dyskinesia.
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval,2017-04-12 14:18:58 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-achieves-best-case-141858404.html?.tsrc=rss,"BMO Capital Markets picked Neurocrine Biosciences, Inc. . (NASDAQ: NBIX ) to Outperform expectations on Wednesday, one day after the the U.S. Food and Drug Administration approved the pharmaceutical company’s ..."
NBIX,NBIX:UW,BBG000GJTN99,Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder,2017-04-12 14:05:23 +0000,http://finance.yahoo.com/r/5fe34194-4cf0-313c-9c5d-ab18ac1e67f9/104399908?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104399908&yptr=yahoo&.tsrc=rss,"Neurocrine says the FDA has approved Ingrezza, the only drug for treatment of adults with tardive dyskinesia."
NBIX,NBIX:UW,BBG000GJTN99,"Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents",2017-04-12 13:32:00 +0000,http://finance.yahoo.com/r/0f72a008-31dc-340d-b957-01c7d894bcb1/biotech-movers-neurocrine-biosciences-leaps-on-drug-approval-synergy-pharma-issued-three-patents.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The company's shares were up 24% ahead of market's open on an FDA approval.
NBIX,NBIX:UW,BBG000GJTN99,"Pre-Market Most Active for Apr 12, 2017 :  MFG, BBRY, SYT, MT, RIG, NADL, NBIX, VAL, NOVN, XIV, ERIC, TSCO",2017-04-12 12:54:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U6leJNHNBlE/pre-market-most-active-for-apr-12-2017-mfg-bbry-syt-mt-rig-nadl-nbix-val-novn-xiv-eric-tsco-cm773077,The NASDAQ 100 Pre Market Indicator is down 2 68 to 5 395 72 The total Pre Market volume is currently 10 551 688 shares traded The following are the most active stocks for the pre market session Mizuho Financial Group Inc MFG is 0 04 at 3 52 with 1 800 000
NBIX,NBIX:UW,BBG000GJTN99,Story Stocks from Briefing.com,2017-04-12 12:48:16 +0000,http://finance.yahoo.com/news/story-stocks-briefing-com-175403381.html?.tsrc=rss,Story Stocks from Briefing.com
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Inc. (NBIX) Is Surging After FDA Approval,2017-04-12 09:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mm_DkLKy_cw/neurocrine-biosciences-inc-nbix-is-surging-after-fda-approval-20170412-00648,Neurocrine Biosciences Inc. (NBIX) Is Surging After FDA Approval
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences gets FDA's OK for movement disorder drug,2017-04-12 00:05:59 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-gets-fdas-ok-000559799.html?.tsrc=rss,"The U.S. Food and Drug Administration  approved Neurocrine Biosciences Inc's drug to treat  tardive dyskinesia, a side effect of antipsychotic medications  characterized by uncontrolled movements of the face and body,  the company said.  Shares of the San Diego-based company were up about 18.5  percent to $49.15 after the closing bell on Tuesday.  The drug, Ingrezza, is the first treatment to be approved  for the irreversible disorder, which occurs in 5 percent to 8  percent of patients taking antipsychotic drugs."
NBIX,NBIX:UW,BBG000GJTN99,"FDA Approves 1st Drug For Tardive Dyskinesia, AGRX On Track, ITEK, AZRX On Watch",2017-04-11 22:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3U2UdDfuC1I/fda-approves-1st-drug-for-tardive-dyskinesia-agrx-on-track-itek-azrx-on-watch-20170411-01284,"FDA Approves 1st Drug For Tardive Dyskinesia, AGRX On Track, ITEK, AZRX On Watch"
NBIX,NBIX:UW,BBG000GJTN99,FDA Oks Neurocrine's Ingrezza Capsules To Treat Adults With Tardive Dyskinesia,2017-04-11 22:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LwCUAbfs0Iw/fda-oks-neurocrines-ingrezza-capsules-to-treat-adults-with-tardive-dyskinesia-20170411-01281,FDA Oks Neurocrine's Ingrezza Capsules To Treat Adults With Tardive Dyskinesia
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (with multimedia),2017-04-11 21:37:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-fda-approval-ingrezza-213700392.html?.tsrc=rss,"SAN DIEGO, April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).  ""The often debilitating effects of tardive dyskinesia have left people feeling isolated and forgotten.  The approval of INGREZZA represents a turning point for these patients and their care partners, offering a meaningful treatment where before there was little hope,"" said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine surges after FDA approval for neurological disorder medication,2017-04-11 21:35:51 +0000,http://finance.yahoo.com/r/2450bb7d-3d4e-3972-a6f4-e712925b4844/Story.aspx?guid=D6F904FE-1C57-4964-8164-3DCF1A4220E9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Neurocrine Biosciences Inc. surged in Tuesday's extended session after the biotechnology company said it received Food and Drug Administration approval for Ingrezza to treat tardive dyskinesia, ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug,2017-04-11 21:19:00 +0000,http://finance.yahoo.com/r/0558d86b-4f0c-35b2-aee5-cf2b822fedf4/neurocrine-biosciences-snags-u-s-approval-for-movement-disorder-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The U.S. Food and Drug Administration granted Ingrezza a relatively clean label that does not include a black box safety warning against suicidality or depression.
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences gets FDA OK for movement disorder drug,2017-04-11 21:17:31 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-gets-fda-ok-211731618.html?.tsrc=rss,"The U.S. Food and Drug Administration  on Tuesday approved Neurocrine Biosciences Inc's drug  to treat tardive dyskinesia, a side effect of antipsychotic  medications characterized by uncontrolled movement of the face  and body, the company said.  The drug, Ingrezza, is the first treatment to be approved for  the irreversible disorder, which occurs in 5 percent to 8  percent of patients taking antipsychotic drugs.  Wall Street analysts, on average, forecast annual sales for  the drug of around $700 million by 2023, according to Thomson  Reuters data."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD),2017-04-11 20:52:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-fda-approval-ingrezza-205200599.html?.tsrc=rss,"SAN DIEGO, April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZATM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).  ""The often debilitating effects of tardive dyskinesia have left people feeling isolated and forgotten.  The approval of INGREZZA represents a turning point for these patients and their care partners, offering a meaningful treatment where before there was little hope,"" said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Repros' Proellex Continues to be Under Partial Clinical Hold,2017-04-11 16:57:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8VX5f1eTWFM/repros-proellex-continues-to-be-under-partial-clinical-hold-cm772809,Repros Therapeutics RPRX announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver Regulators will be consulting agency experts
NBIX,NBIX:UW,BBG000GJTN99,AbbVie's Elagolix Meets Primary Endpoint in Phase II Study,2017-04-10 16:55:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fo3PwiBWt88/abbvies-elagolix-meets-primary-endpoint-in-phase-ii-study-cm772211,AbbVie Inc ABBV along with Neurocrine Biosciences Inc NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids The data from the study were presented at the
NBIX,NBIX:UW,BBG000GJTN99,AbbVie&apos;s Elagolix Meets Primary Endpoint in Phase II Study,2017-04-10 14:48:02 +0000,http://finance.yahoo.com/news/abbvie-apos-elagolix-meets-primary-144802174.html?.tsrc=rss,"AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids."
NBIX,NBIX:UW,BBG000GJTN99,"AKRX Confirms Acquisition Talks, CBIO Plunges, Be All Ears For GERN",2017-04-09 19:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PxysMOkMLBc/akrx-confirms-acquisition-talks-cbio-plunges-be-all-ears-for-gern-20170409-00034,"AKRX Confirms Acquisition Talks, CBIO Plunges, Be All Ears For GERN"
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids,2017-04-07 12:00:00 +0000,http://finance.yahoo.com/news/abbvie-announces-positive-phase-2b-120000226.html?.tsrc=rss,"NORTH CHICAGO, Ill., April 7, 2017 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NBIX), today announced detailed results from a Phase 2b clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy (estradiol/norethindrone acetate) compared to placebo.  The data demonstrated that elagolix, with and without add-back therapy, met the primary efficacy endpoint of reduced heavy menstrual bleeding as compared to placebo (p<0.001).  The study's primary endpoint assessed the change in menstrual blood loss from baseline to month six utilizing the alkaline hematin method, a standard measurement for menstrual blood loss."
NBIX,NBIX:UW,BBG000GJTN99,AbbVie: Data Shows Elagolix Reduces Menstrual Bleeding In Phase 2b Trial,2017-04-07 08:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6I1pY9c6I0w/abbvie-data-shows-elagolix-reduces-menstrual-bleeding-in-phase-2b-trial-20170407-00332,AbbVie: Data Shows Elagolix Reduces Menstrual Bleeding In Phase 2b Trial
NBIX,NBIX:UW,BBG000GJTN99,"ETFs with exposure to Neurocrine Biosciences, Inc. : April 5, 2017",2017-04-05 21:08:41 +0000,http://finance.yahoo.com/r/2cbcfa94-abc4-30a7-8e8e-a4b781592476/etfs-with-exposure-to-neurocrine-biosciences-inc-april-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neurocrine Biosciences, Inc. Here are 5 ETFs with the largest exposure to NBIX-US. Comparing the performance and risk of Neurocrine Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
NBIX,NBIX:UW,BBG000GJTN99,Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Neurocrine Biosciences,2017-04-05 11:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-stocks-watch-113000430.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 5, 2017 / Teva Pharmaceutical Industries and Neurocrine Biosciences will be racing for the FDA approval for their treatments of tardive dyskinesia, revealed an analyst ..."
NBIX,NBIX:UW,BBG000GJTN99,"Noteworthy Tuesday Option Activity: TREE, NBIX, INTC",2017-04-04 21:23:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7c9KeIxn8Lg/noteworthy-tuesday-option-activity-tree-nbix-intc-cm769834,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in LendingTree Inc Symbol TREE where a total volume of 625 contracts has been traded thus far today a contract volume which is representative of approximately 62 500
NBIX,NBIX:UW,BBG000GJTN99,"Teva Pharma, Neurocrine Do Battle Over Neurological Treatments",2017-04-04 20:36:45 +0000,http://finance.yahoo.com/r/ba691c1d-93a3-33be-9082-1bf8eb0bcdcc/teva-pharma-neurocrine-prep-for-donnybrook-in-tourettes?src=A00220A&yptr=yahoo&.tsrc=rss,"Teva and Neurocrine look likely to compete this year as the FDA mulls drugs from them to treat involuntary movements, an analyst said Tuesday."
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : April 3, 2017",2017-04-03 12:18:32 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-april-3-2017/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : April 3, 2017"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : April 3, 2017",2017-04-03 12:18:32 +0000,http://finance.yahoo.com/r/c8768b65-b5bf-3339-9d24-7eb9001b8f41/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-april-3-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
NBIX,NBIX:UW,BBG000GJTN99,4 Drug Stocks With Big News Coming in April,2017-04-02 17:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2_bq9BTaeoA/4-drug-stocks-with-big-news-coming-in-april-cm768806,Fill in the blank April brings Some might say that April brings April showers Others eyeing the calendar with dread might say that April brings tax day But for four drugmakers April brings big news that could be catalysts for their stocks Here s what s coming up this month
NBIX,NBIX:UW,BBG000GJTN99,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,https://www.fool.com/investing/2017/04/02/4-drug-stocks-with-big-news-coming-in-april.aspx,4 Drug Stocks With Big News Coming in April
NBIX,NBIX:UW,BBG000GJTN99,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,http://finance.yahoo.com/r/706729f1-72a5-3e3c-a956-8d7dbde1451c/4-drug-stocks-with-big-news-coming-in-april.aspx?yptr=yahoo&.tsrc=rss,"Major FDA decisions are on the way this month for Neurocrine, Incyte, Lilly, and BioMarin."
NBIX,NBIX:UW,BBG000GJTN99,What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track,2017-03-31 20:10:50 +0000,http://www.investors.com/news/technology/what-does-big-pharma-want-to-buy-3-drugmakers-on-ma-track/?src=A00220A,What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track
NBIX,NBIX:UW,BBG000GJTN99,"Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive",2017-03-24 19:18:09 +0000,http://finance.yahoo.com/news/setting-stage-neurocrines-pending-pdufa-191809198.html,"Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive"
NBIX,NBIX:UW,BBG000GJTN99,"Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive",2017-03-24 19:18:09 +0000,http://finance.yahoo.com/news/setting-stage-neurocrines-pending-pdufa-191809198.html?.tsrc=rss,"Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) is on the verge of becoming a commercial biotech company, as its PDUFA date for Ingrezza in tardive dyskynesia (TD) approaches. The FDA is expected to announce ..."
NBIX,NBIX:UW,BBG000GJTN99,Biotech Stocks Facing FDA Decision In April,2017-03-24 06:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/70ZD2H6sCX8/biotech-stocks-facing-fda-decision-in-april-20170324-00160,Biotech Stocks Facing FDA Decision In April
NBIX,NBIX:UW,BBG000GJTN99,9:00 am Neurocrine Biosci announces the American Journal of Psychiatry published results from Kinect 3 Phase III Study of Ingrezza for the treatment of tardive dyskinesia; study met its primary endpoint,2017-03-21 13:00:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#nbix,9:00 am Neurocrine Biosci announces the American Journal of Psychiatry published results from Kinect 3 Phase III Study of Ingrezza for the treatment of tardive dyskinesia; study met its primary endpoint
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia,2017-03-21 12:59:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-american-journal-psychiatry-125900730.html?.tsrc=rss,"SAN DIEGO, March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive results from the Kinect 3 Phase III study of INGREZZA (valbenazine) for the treatment of tardive dyskinesia (TD) were published online by the American Journal of Psychiatry (DOI: 10.1176/appi.ajp.2017.16091037).  Once-daily INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, demonstrated a significant and meaningful reduction in TD symptoms compared with placebo in participants with underlying schizophrenia, schizoaffective disorder or mood disorder.  Tardive dyskinesia is thought to affect at least 500,000 people in the U.S. and is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face.  These symptoms are associated with chronic exposure to dopamine receptor blockers such as antipsychotic medications and can be severe, persistent and irreversible."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia,2017-03-21 12:59:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-american-journal-psychiatry-125900730.html,"[PR Newswire] - SAN DIEGO, March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive results from the Kinect 3 Phase III study of INGREZZA (valbenazine) for the treatment of tardive dyskinesia (TD) were published online by the American Journal of Psychiatry (DOI: 10.1176/appi.ajp.2017.16091037). Once-daily INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, demonstrated a significant and meaningful reduction in TD symptoms compared with placebo in participants with underlying schizophrenia, schizoaffective disorder or mood disorder. Tardive dyskinesia is thought to affect at least 500,000 people in the U.S. and is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. These symptoms are associated with chronic exposure to dopamine receptor blockers such as antipsychotic medications and can be severe, persistent and irreversible."
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events",2017-03-13 10:06:11 +0000,http://biz.yahoo.com/e/170313/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events"
NBIX,NBIX:UW,BBG000GJTN99,"Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ...",2017-03-11 00:11:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EnI2WYygFWA/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-cm759336,Perceptive Advisors Llc New Purchases GLPG AVDL ACOR IRTC CTMX BCRX ATRS JAZZ ALNY PPHMP Added Positions NBIX ACRS FOLD ANIP AVXS GBT ARDX VBIV ZGNX XNCR Reduced Positions SRPT AERI CRBP ABMD SUPN AGEN BPMC NDRM AGTC
NBIX,NBIX:UW,BBG000GJTN99,NBIX Crosses Above Key Moving Average Level,2017-03-11 00:10:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cIHioxpSQg4/nbix-crosses-above-key-moving-average-level-cm759314,In trading on Friday shares of Neurocrine Biosciences Inc Symbol NBIX crossed above their 200 day moving average of 46 31 changing hands as high as 46 42 per share Neurocrine Biosciences Inc shares are currently trading up about 3 2 on the day The chart below shows the one
NBIX,NBIX:UW,BBG000GJTN99,NEUROCRINE BIOSCIENCES INC Financials,2017-02-18 18:04:10 +0000,http://finance.yahoo.com/q/is?s=nbix,NEUROCRINE BIOSCIENCES INC Financials
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017",2017-02-16 17:34:31 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-nbix-us-earnings-analysis-2016-by-the-numbers-february-16-2017/,"Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017",2017-02-16 17:34:31 +0000,http://finance.yahoo.com/r/8c78d350-cbb8-300a-b920-4cc0608e73b0/neurocrine-biosciences-inc-nbix-us-earnings-analysis-2016-by-the-numbers-february-16-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Neurocrine Biosciences, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Neurocrine Biosciences, Inc. – Palatin Technologies, Inc., Pfizer Inc., Eli Lilly and Company and AbbVie, Inc. (PTN-US, PFE-US, LLY-US and ABBV-US) that have also reported for this period. ... Read more    
<b>(Read more...)</b>"
NBIX,NBIX:UW,BBG000GJTN99,NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease,2017-02-16 17:00:00 +0000,http://finance.yahoo.com/news/nbix-acquires-north-american-rights-170000874.html?.tsrc=rss,"ONGENTYS® is a once-daily, highly-selective catechol-O-methyltransferase (COMT) inhibitor that was approved in June 2016 by the European Medicines Agency (EMA) as an adjunct therapy along with levodopa/DOPA decarboxylase inhibitors for adults with Parkinson’s disease.  Parkinson’s disease (PD) is a slowly progressing neurological disorder characterized by tremor, stiffness, slow and decreased movement, and postural instability affecting approximately 0.4% of the population over age 40 and 1% of those over age 65 (Merck Manual)."
NBIX,NBIX:UW,BBG000GJTN99,NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease,2017-02-16 17:00:00 +0000,http://finance.yahoo.com/news/nbix-acquires-north-american-rights-170000874.html,NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease
NBIX,NBIX:UW,BBG000GJTN99,[2/15] Today's Top 10 Long/Short Estimize Signal Scores,2017-02-15 20:23:04 +0000,http://finance.yahoo.com/tumblr/blog-215-todays-top-10-longshort-estimize-signal-203907487.html,[2/15] Today's Top 10 Long/Short Estimize Signal Scores
NBIX,NBIX:UW,BBG000GJTN99,Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT,2017-02-15 03:30:50 +0000,http://finance.yahoo.com/news/edited-transcript-nbix-earnings-conference-033050888.html?.tsrc=rss,Q4 2016 Neurocrine Biosciences Inc Earnings Call
NBIX,NBIX:UW,BBG000GJTN99,Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT,2017-02-15 03:30:50 +0000,http://finance.yahoo.com/news/edited-transcript-nbix-earnings-conference-033050888.html,Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an",2017-02-14 21:35:32 +0000,http://biz.yahoo.com/e/170214/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 4Q loss,2017-02-14 21:19:29 +0000,http://sg.finance.yahoo.com/news/neurocrine-reports-4q-loss-211929577.html,Neurocrine reports 4Q loss
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 4Q loss,2017-02-14 21:19:29 +0000,http://finance.yahoo.com/news/neurocrine-reports-4q-loss-211929764.html?.tsrc=rss,The San Diego-based company said it had a loss of 51 cents per share. The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss ...
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017,2017-02-14 21:01:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-reports-end-2016-210100968.html,"[PR Newswire] - SAN DIEGO, Feb. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and full year 2016, and highlighted recent progress on its pipeline. ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017,2017-02-14 21:01:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-reports-end-2016-210100968.html?.tsrc=rss,"SAN DIEGO, Feb. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and full year 2016, and highlighted recent progress on its pipeline. ..."
NBIX,NBIX:UW,BBG000GJTN99,"After-Hours Earnings Report for February 14, 2017 :  AIG, ESRX, DVN, A, FANG, ENLK, FLIR, MASI, NBIX, HE, RPAI, ENLC",2017-02-14 20:14:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X00v_Eyx0Kk/after-hours-earnings-report-for-february-14-2017-aig-esrx-dvn-a-fang-enlk-flir-masi-nbix-he-rpai-enlc-cm747825,The following companies are expected to report earnings after hours on 02 14 2017 Visit our Earnings Calendar for a full list of expected earnings releases American International Group Inc AIG is reporting for the quarter ending December 31 2016
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Q4 16 Earnings Conference Call At 5:00 PM ET,2017-02-14 15:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qPi0LlmmoI0/neurocrine-biosciences-q4-16-earnings-conference-call-at-500-pm-et-20170214-01238,Neurocrine Biosciences Q4 16 Earnings Conference Call At 5:00 PM ET
NBIX,NBIX:UW,BBG000GJTN99,Q4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close,2017-02-14 12:07:02 +0000,http://biz.yahoo.com/research/earncal/20170214.html?t=nbix,Q4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri",2017-02-10 21:33:02 +0000,http://biz.yahoo.com/e/170210/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Inks $145 Million Parkinson's Drug Deal,2017-02-10 15:18:00 +0000,http://www.investopedia.com/news/neurocrine-inks-145m-parkinsons-drug-deal-nbix/?partner=YahooSA,Neurocrine Inks $145 Million Parkinson's Drug Deal
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Inks $145 Million Parkinson's Drug Deal,2017-02-10 15:18:00 +0000,http://finance.yahoo.com/r/71ba1f55-caa9-3930-bace-8674ea0190b3/neurocrine-inks-145m-parkinsons-drug-deal-nbix?partner=YahooSA&yptr=yahoo&.tsrc=rss,Neurocrine gets North American rights for BIAL’s established Ongentys drug which is already approved in the EU
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone,2017-02-09 21:01:00 +0000,http://finance.yahoo.com/news/neurocrine-bial-announce-exclusive-north-210100206.html,"[PR Newswire] - SAN DIEGO and PORTO, Portugal, Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America. ONGENTYS® (opicapone) is a once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor) that was approved in June 2016 by the European Commission as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. ""Securing the commercial rights to opicapone in the United States and Canada is another important step in expanding our movement disorders franchise,"" said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone,2017-02-09 21:01:00 +0000,http://finance.yahoo.com/news/neurocrine-bial-announce-exclusive-north-210100206.html?.tsrc=rss,"SAN DIEGO and PORTO, Portugal, Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America.  ONGENTYS® (opicapone) is a once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor) that was approved in June 2016 by the European Commission as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations.  ""Securing the commercial rights to opicapone in the United States and Canada is another important step in expanding our movement disorders franchise,"" said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results,2017-02-07 18:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-announces-conference-call-180000136.html?.tsrc=rss,"SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market closes on Tuesday, ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results,2017-02-07 18:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-announces-conference-call-180000136.html,"[PR Newswire] - SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market closes on Tuesday, ..."
NBIX,NBIX:UW,BBG000GJTN99,[2/7] Today's Top 10 Long/Short Estimize Signal Scores,2017-02-07 15:35:15 +0000,http://finance.yahoo.com/tumblr/blog-27-todays-top-10-longshort-estimize-signal-173501600.html,[2/7] Today's Top 10 Long/Short Estimize Signal Scores
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : February 1, 2017",2017-02-01 12:35:03 +0000,http://finance.yahoo.com/r/d311dad4-bbd9-3918-adaf-c522934ef4ca/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-february-1-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : February 1, 2017",2017-02-01 12:35:03 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-february-1-2017/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : February 1, 2017"
NBIX,NBIX:UW,BBG000GJTN99,"Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen",2017-01-27 14:46:00 +0000,http://finance.yahoo.com/r/6d8e5f15-edfa-3df7-8977-543e9c7c9c72/premarket-biotech-movers-neurocrine-biosciences-aralez-pharmaceuticals-qiagen.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday."
NBIX,NBIX:UW,BBG000GJTN99,"Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen",2017-01-27 14:46:00 +0000,https://www.thestreet.com/story/13969574/1/premarket-biotech-movers-neurocrine-biosciences-aralez-pharmaceuticals-qiagen.html?puc=yahoo&cm_ven=YAHOO,"Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosci upgraded by Oppenheimer,2017-01-27 12:09:48 +0000,http://finance.yahoo.com/q/ud?s=NBIX,Neurocrine Biosci upgraded by Oppenheimer
NBIX,NBIX:UW,BBG000GJTN99,The Implied Analyst 12-Month Target For PBE,2017-01-24 15:32:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M7mvj0cWhO8/the-implied-analyst-12-month-target-for-pbe-cm737250,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
NBIX,NBIX:UW,BBG000GJTN99,NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint,2017-01-19 18:30:00 +0000,http://finance.yahoo.com/news/nbix-phase-2-study-ingrezza-183000712.html?.tsrc=rss,"The study did not achieve the pre-specified primary endpoint, which was the change from baseline in the Yale Global Tic Severity Scale (YGTSS) at Week 8 (P=0.18).  Due to the fact that a number of the same investigators from the T-Forward study are also taking part in the T-Force GREEN study of INGREZZA™ in children and adolescents with Tourette syndrome, the company did not release many details of the results in order to avoid potentially introducing assessor bias into the T-Force GREEN study.  Tourette syndrome (TS) is a childhood neuropsychiatric disorder that is characterized by repetitive movements and unwanted sounds that are not easily controlled."
NBIX,NBIX:UW,BBG000GJTN99,NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint,2017-01-19 18:30:00 +0000,http://finance.yahoo.com/news/nbix-phase-2-study-ingrezza-183000712.html,NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint
NBIX,NBIX:UW,BBG000GJTN99,"ADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study",2017-01-18 02:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VJpUu1hzaR8/adhd-doesnt-measure-up-jazz-abuzz-nbix-slips-on-failed-study-20170118-00069,"ADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study"
NBIX,NBIX:UW,BBG000GJTN99,"After hours buzz: CSX, UAL, GIMO & more",2017-01-17 22:55:23 +0000,http://www.cnbc.com/id/104223843?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104223843,"After hours buzz: CSX, UAL, GIMO & more"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down",2017-01-17 22:28:37 +0000,http://www.investors.com/news/technology/pharma-stocks-topple-late-after-neurocrines-tourette-med-fails/,"Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients,2017-01-17 21:19:00 +0000,https://www.thestreet.com/story/13956669/1/neurocrine-drug-fails-to-reduce-tic-severity-in-tourette-syndrome-patients.html?puc=yahoo&cm_ven=YAHOO,Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome,2017-01-17 21:01:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-completion-phase-ii-210100835.html,"[PR Newswire] - While the study showed a significant improvement in overall symptoms of Tourette syndrome as evidenced by the Clinical Global Impression of Change (p=0.015), the pre-specified primary endpoint, the change-from-baseline in the Yale Global Tic Severity Scale (YGTSS) at Week 8 was not met (p=0.18). Adverse events were dose dependent and consistent with earlier clinical studies. ""Overall we were very pleased with the conduct of the study, including the investigators' administration of the Yale Global Tic Severity Scale as well as the safety profile of INGREZZA in adults with Tourette syndrome,"" said Chris O'Brien, Chief Medical Officer of Neurocrine."
NBIX,NBIX:UW,BBG000GJTN99,Here Are Two Market Moving Biotech Catalysts To Watch This Week,2017-01-17 14:40:44 +0000,http://www.insidermonkey.com/blog/here-are-two-market-moving-biotech-catalysts-to-watch-this-week-519026/,Here Are Two Market Moving Biotech Catalysts To Watch This Week
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017",2017-01-11 16:15:25 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-value-analysis-nasdaqnbix-january-11-2017/,"Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017",2017-01-10 12:22:32 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-january-10-2017/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017"
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex",2017-01-06 21:32:04 +0000,http://biz.yahoo.com/e/170106/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex"
NBIX,NBIX:UW,BBG000GJTN99,NBIX: AdComm Meeting for INGREZZA™ Cancelled by FDA,2017-01-06 19:00:00 +0000,http://finance.yahoo.com/news/nbix-adcomm-meeting-ingrezza-cancelled-190000457.html,NBIX: AdComm Meeting for INGREZZA™ Cancelled by FDA
NBIX,NBIX:UW,BBG000GJTN99,"What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)?",2017-01-06 15:28:17 +0000,http://www.insidermonkey.com/blog/what-does-the-panel-cancellation-mean-for-neurocrine-biosciences-inc-nbix-514946/,"What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)?"
NBIX,NBIX:UW,BBG000GJTN99,These 5 Biotech Stocks Could Be Big Takeover Targets in 2017,2017-01-06 13:35:11 +0000,http://finance.yahoo.com/news/5-biotech-stocks-could-big-133511110.html,These 5 Biotech Stocks Could Be Big Takeover Targets in 2017
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer,2017-01-06 13:30:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-announces-appointment-david-133000368.html,"[PR Newswire] - ""Neurocrine is very pleased to welcome Dr. Gros as our President and Chief Operating Officer as we move forward with our transformation into a commercial entity,"" said Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences. ""Neurocrine is a remarkably innovative company, leading the development of novel therapeutics to address major unmet needs in neurological and endocrine disorders,"" said Dr. Gros."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Inc. (NBIX) Is Up Sharply After FDA Cancels Meeting,2017-01-06 09:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qytZj8TqLyY/neurocrine-biosciences-inc-nbix-is-up-sharply-after-fda-cancels-meeting-20170106-00345,Neurocrine Biosciences Inc. (NBIX) Is Up Sharply After FDA Cancels Meeting
NBIX,NBIX:UW,BBG000GJTN99,"OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC",2017-01-06 01:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yOqldRF18G8/otic-hits-right-notes-gemp-to-report-data-this-month-busy-year-ahead-for-rvnc-20170106-00017,"OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Says FDA Cancels Psychopharmacologic Drugs Advisory Committee Meeting,2017-01-05 21:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ItTaPR4eeWc/neurocrine-says-fda-cancels-psychopharmacologic-drugs-advisory-committee-meeting-20170105-01248,Neurocrine Says FDA Cancels Psychopharmacologic Drugs Advisory Committee Meeting
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia,2017-01-05 21:55:11 +0000,http://www.publicnow.com/view/CC42E7E81A38A150454CCEC6B3F77EA6D215B69A,"[at noodls] - SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™(valbenazine) ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia,2017-01-05 21:01:00 +0000,http://finance.yahoo.com/news/neurocrine-provides-fda-advisory-committee-210100122.html,"[PR Newswire] - SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™ (valbenazine) New Drug Application (NDA), has decided to cancel the Psychopharmacologic Drugs Advisory Committee meeting which was originally scheduled for February 16, 2017. The FDA informed the Company that the Priority Review of the NDA of INGREZZA for the treatment of tardive dyskinesia is continuing as planned with the previously announced Prescription Drug User Fee Act (PDUFA) target action date of April 11, 2017."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference,2017-01-03 18:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-35th-annual-180000208.html,"[PR Newswire] - SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 35 th Annual ..."
NBIX,NBIX:UW,BBG000GJTN99,7 Key FDA Decisions and Catalysts Expected in January and February,2016-12-30 12:45:32 +0000,http://247wallst.com/healthcare-business/2016/12/30/7-key-fda-decisions-and-catalysts-expected-in-january-and-february/,7 Key FDA Decisions and Catalysts Expected in January and February
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers",2016-12-23 21:22:10 +0000,http://biz.yahoo.com/e/161223/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down,2016-12-21 22:12:08 +0000,http://www.publicnow.com/view/8C0ACDAF564A882A79AB2A8733BDF48D7E19633C,"[at noodls] - SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that Timothy P. Coughlin ..."
NBIX,NBIX:UW,BBG000GJTN99,3 Low-Volatility Biotech Stocks to Buy,2016-12-18 19:56:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/czbWM7lu0JY/3-low-volatility-biotech-stocks-to-buy-cm723007,Are you hesitant to buy biotech stocks because of their volatility If so it s understandable Many biotech stocks are very volatile with frequent big swings up and down However there are some biotechs that have relatively low volatility If you re wary of biotechs here s why
NBIX,NBIX:UW,BBG000GJTN99,3 Low-Volatility Biotech Stocks to Buy,2016-12-18 18:36:39 +0000,http://www.fool.com/investing/2016/12/18/3-biotech-stocks-to-buy-if-youre-wary-of-biotechs.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Low-Volatility Biotech Stocks to Buy
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences To Participate In BMO Capital Market Conference At 8:00AM,2016-12-14 07:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Iguv9gQyXkg/neurocrine-biosciences-to-participate-in-bmo-capital-market-conference-at-800am-20161214-00178,Neurocrine Biosciences To Participate In BMO Capital Market Conference At 8:00AM
NBIX,NBIX:UW,BBG000GJTN99,"Should You Follow the Smart Money Stampede Out of Equity One, Inc. (EQY)?",2016-12-09 19:26:29 +0000,http://www.insidermonkey.com/blog/should-you-follow-the-smart-money-stampede-out-of-equity-one-inc-eqy-503425/,"Should You Follow the Smart Money Stampede Out of Equity One, Inc. (EQY)?"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference,2016-12-07 18:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-2016-bmo-180000918.html,"[PR Newswire] - SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference in New York City. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month."
NBIX,NBIX:UW,BBG000GJTN99,Hedge Funds Are Dumping CSRA Inc (CSRA),2016-12-06 14:49:38 +0000,http://www.insidermonkey.com/blog/hedge-funds-are-dumping-csra-inc-csra-499506/,Hedge Funds Are Dumping CSRA Inc (CSRA)
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology,2016-12-05 22:30:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-announces-ingrezza-valbenazine-223000671.html,"[PR Newswire] - SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that two abstracts representing additional data from several clinical trials of the investigational drug INGREZZATM (valbenazine) are being presented at the Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Florida. The posters include an evaluation of the safety and effectiveness of long-term dosing of INGREZZA in the treatment of tardive dyskinesia. ""We are pleased to share the positive and compelling long-term treatment data of INGREZZA in tardive dyskinesia patients with the broader scientific community,"" said Chris O'Brien, M.D. Chief Medical Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Uterine Fibroids Segment May Offer Opportunity for NBIX,2016-12-02 16:05:11 +0000,http://marketrealist.com/2016/12/uterine-fibroids-segment-may-offer-strong-growth-opportunity-neurocrine-biosciences-future/?utm_source=yahoo&utm_medium=feed,Uterine Fibroids Segment May Offer Opportunity for NBIX
NBIX,NBIX:UW,BBG000GJTN99,"ETFs with exposure to Neurocrine Biosciences, Inc. : December 2, 2016",2016-12-02 15:57:07 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-neurocrine-biosciences-inc-december-2-2016/,"ETFs with exposure to Neurocrine Biosciences, Inc. : December 2, 2016"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix,2016-12-02 15:04:46 +0000,http://marketrealist.com/2016/12/neurocrine-biosciences-expected-penetrate-womens-health-segment-elagolix/?utm_source=yahoo&utm_medium=feed,Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix
NBIX,NBIX:UW,BBG000GJTN99,NBIX Continues to Study Valbenazine for Tourette Syndrome,2016-12-02 13:05:07 +0000,http://marketrealist.com/2016/12/neurocrine-biosciences-continues-explore-valbenazine-tourette-syndrome-indication/?utm_source=yahoo&utm_medium=feed,NBIX Continues to Study Valbenazine for Tourette Syndrome
NBIX,NBIX:UW,BBG000GJTN99,NBIX Crosses Below Key Moving Average Level,2016-12-01 18:17:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R5hGd8Koh3E/nbix-crosses-below-key-moving-average-level-cm716454,In trading on Thursday shares of Neurocrine Biosciences Inc Symbol NBIX crossed below their 200 day moving average of 45 90 changing hands as low as 43 97 per share Neurocrine Biosciences Inc shares are currently trading off about 5 2 on the day The chart below shows the one
NBIX,NBIX:UW,BBG000GJTN99,Why Valbenazine Studies Seem Promising,2016-12-01 18:04:07 +0000,http://marketrealist.com/2016/12/valbenazine-may-become-effective-treatment-option-tardive-dyskinesia-patients-future-years/?utm_source=yahoo&utm_medium=feed,Why Valbenazine Studies Seem Promising
NBIX,NBIX:UW,BBG000GJTN99,Should You Avoid Navient Corp (NAVI)?,2016-12-01 17:55:07 +0000,http://www.insidermonkey.com/blog/should-you-avoid-navient-corp-navi-492292/,Should You Avoid Navient Corp (NAVI)?
NBIX,NBIX:UW,BBG000GJTN99,"Is Neurocrine Biosciences, Inc. (NBIX) a Good Stock to Buy?",2016-12-01 17:18:59 +0000,http://www.insidermonkey.com/blog/is-neurocrine-biosciences-inc-nbix-a-good-stock-to-buy-491027/,"Is Neurocrine Biosciences, Inc. (NBIX) a Good Stock to Buy?"
NBIX,NBIX:UW,BBG000GJTN99,Valbenazine May Become a Leading Therapy for Tardive Dyskinesia,2016-12-01 16:05:50 +0000,http://marketrealist.com/2016/12/valbenazine-may-become-leading-therapy-tardive-dyskinesia-future-years/?utm_source=yahoo&utm_medium=feed,Valbenazine May Become a Leading Therapy for Tardive Dyskinesia
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences (Nasdaq: NBIX) to Ring The Nasdaq Stock Market Opening Bell,2016-12-01 15:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-nasdaq-nbix-ring-150000281.html,"[GlobeNewswire] - What: Neurocrine Biosciences, a company that discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological ..."
NBIX,NBIX:UW,BBG000GJTN99,Why Neurocrine Biosciences May See Higher Losses in 2016,2016-12-01 14:25:25 +0000,http://marketrealist.com/2016/12/neurocrine-biosciences-may-witness-rise-losses-2016/?utm_source=yahoo&utm_medium=feed,Why Neurocrine Biosciences May See Higher Losses in 2016
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : December 1, 2016",2016-12-01 12:36:56 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bearish-manner-nbix-us-december-1-2016/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : December 1, 2016"
NBIX,NBIX:UW,BBG000GJTN99,Is Pool Corporation (POOL) A Good Stock To Buy?,2016-12-01 00:25:01 +0000,http://www.insidermonkey.com/blog/is-pool-corporation-pool-a-good-stock-to-buy-492903/,Is Pool Corporation (POOL) A Good Stock To Buy?
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences To Participate In Piper Jaffray Conference At 11:00 AM ET,2016-11-30 10:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KXEz6VfqC7o/neurocrine-biosciences-to-participate-in-piper-jaffray-conference-at-1100-am-et-20161130-00667,Neurocrine Biosciences To Participate In Piper Jaffray Conference At 11:00 AM ET
NBIX,NBIX:UW,BBG000GJTN99,"Arrowhead Blunted, CERC Depressed, It's All Clear For NOVN, CPHR Leaves Nasdaq",2016-11-30 01:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7J1NgBDHevE/arrowhead-blunted-cerc-depressed-its-all-clear-for-novn-cphr-leaves-nasdaq-20161130-00022,"Arrowhead Blunted, CERC Depressed, It's All Clear For NOVN, CPHR Leaves Nasdaq"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia,2016-11-29 21:15:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-fda-advisory-committee-211500198.html,"[PR Newswire] - SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in the New Drug Application (NDA) of INGREZZATM (valbenazine) for the treatment of tardive dyskinesia on February 16, 2017. The FDA has granted Priority Review status to the INGREZZA NDA with a Prescription Drug User Fee Act (PDUFA) target action date of April 11, 2017. The NDA for INGREZZA includes the results from the Kinect 2 and Kinect 3 clinical trials which evaluated over 330 tardive dyskinesia patients."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Says FDA Advisory Committee Meeting On Feb. 16 To Review INGREZZA NDA,2016-11-29 20:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A327nWS6xkc/neurocrine-says-fda-advisory-committee-meeting-on-feb-16-to-review-ingrezza-nda-20161129-01199,Neurocrine Says FDA Advisory Committee Meeting On Feb. 16 To Review INGREZZA NDA
NBIX,NBIX:UW,BBG000GJTN99,Elagolix May Become a Strong Growth Driver for AbbVie,2016-11-29 15:04:34 +0000,http://marketrealist.com/2016/11/elagolix-may-become-strong-growth-driver-abbvie-future-years/?utm_source=yahoo&utm_medium=feed,Elagolix May Become a Strong Growth Driver for AbbVie
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference,2016-11-21 22:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-28th-annual-220000184.html,"[PR Newswire] - SAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 28th Annual Piper Jaffray Healthcare Conference in New York City. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month."
NBIX,NBIX:UW,BBG000GJTN99,Ready to Get In on Biotech? Check Out These 3 Stocks,2016-11-21 12:03:50 +0000,http://www.fool.com/investing/2016/11/20/ready-to-get-in-on-biotech-check-out-these-3-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Ready to Get In on Biotech? Check Out These 3 Stocks
NBIX,NBIX:UW,BBG000GJTN99,Ready to Get In on Biotech? Check Out These 3 Stocks,2016-11-20 12:50:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9gaEmWvHvzM/ready-to-get-in-on-biotech-check-out-these-3-stocks-cm711663,There 160 are plenty of reasons for investors to avoid the biotechnology sector altogether The majority of companies from the industry are unprofitable forcing them to constantly raise additional capital Bringing a new drug through the regulatory approval process is
NBIX,NBIX:UW,BBG000GJTN99,Analysts Forecast 20% Gains Ahead For The Holdings of FBT,2016-11-17 15:50:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UdBzIEMb2nY/analysts-forecast-20-gains-ahead-for-the-holdings-of-fbt-cm710532,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : November 11, 2016",2016-11-11 12:15:00 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-november-11-2016/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : November 11, 2016"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Jefferies 2016 London Healthcare Conference,2016-11-10 18:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-jefferies-2016-180000799.html,"[PR Newswire] - SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 London Healthcare Conference in London. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports Third Quarter 2016 Results,2016-11-09 23:11:05 +0000,http://www.publicnow.com/view/D5BA34AB3A3B45D960861D8336D0B40F4B2A822A,"[at noodls] - SAN DIEGO, Nov. 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2016. For the third quarter of 2016, the Company ..."
NBIX,NBIX:UW,BBG000GJTN99,Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed,2016-11-08 17:53:44 +0000,http://www.insidermonkey.com/blog/big-bet-on-sarepta-therapeutics-inc-srpt-lifts-perceptive-advisors-q3-returns-see-how-other-investments-performed-485488/,Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences To Participate In Credit Suisse Conference 11:30 AM ET,2016-11-07 10:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rmR0URucwxw/neurocrine-biosciences-to-participate-in-credit-suisse-conference-1130-am-et-20161107-00866,Neurocrine Biosciences To Participate In Credit Suisse Conference 11:30 AM ET
NBIX,NBIX:UW,BBG000GJTN99,NBIX: Data for Valbenazine in Tourette Syndrome in 1H17,2016-11-04 20:00:00 +0000,http://finance.yahoo.com/news/nbix-data-valbenazine-tourette-syndrome-200000739.html,NBIX: Data for Valbenazine in Tourette Syndrome in 1H17
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences is Now Oversold (NBIX),2016-11-03 18:07:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OqXwlfrrmE0/neurocrine-biosciences-is-now-oversold-nbix-cm703441,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
NBIX,NBIX:UW,BBG000GJTN99,Edited Transcript of NBIX earnings conference call or presentation 2-Nov-16 9:00pm GMT,2016-11-03 03:17:40 +0000,http://finance.yahoo.com/news/edited-transcript-nbix-earnings-conference-031740767.html,Edited Transcript of NBIX earnings conference call or presentation 2-Nov-16 9:00pm GMT
NBIX,NBIX:UW,BBG000GJTN99,This Biotech Hedge Fund’s Stock Picks Killed It in Q3,2016-11-03 02:17:43 +0000,http://www.insidermonkey.com/blog/this-biotech-hedge-funds-stock-picks-killed-it-in-q3-484680/,This Biotech Hedge Fund’s Stock Picks Killed It in Q3
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 3Q loss,2016-11-02 21:31:40 +0000,http://sg.finance.yahoo.com/news/neurocrine-reports-3q-loss-213140381.html,Neurocrine reports 3Q loss
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an",2016-11-02 20:15:36 +0000,http://biz.yahoo.com/e/161102/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports Third Quarter 2016 Results,2016-11-02 20:01:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-reports-third-quarter-200100760.html,"[PR Newswire] - SAN DIEGO, Nov. 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2016. For the third quarter of 2016, the Company ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Q3 16 Earnings Conference Call At 5:00 PM ET,2016-11-02 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3NG4P-yIiAI/neurocrine-biosciences-q3-16-earnings-conference-call-at-500-pm-et-20161102-00543,Neurocrine Biosciences Q3 16 Earnings Conference Call At 5:00 PM ET
NBIX,NBIX:UW,BBG000GJTN99,Q3 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close,2016-11-02 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20161102.html?t=nbix,Q3 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Credit Suisse 25th Annual Healthcare Conference,2016-10-31 17:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-credit-suisse-170000237.html,"[PR Newswire] - SAN DIEGO, Oct. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Credit Suisse ..."
NBIX,NBIX:UW,BBG000GJTN99,"Research Reports Coverage on Generic Drugs Stocks -- Evoke Pharma, Catalyst Pharma, Neurocrine Biosciences, and Galectin Therapeutics",2016-10-31 15:15:00 +0000,http://finance.yahoo.com/news/research-reports-coverage-generic-drugs-151500992.html,"[PR Newswire] - Stock-Callers.com has initiated coverage on four Generic Drugs companies, namely: Evoke Pharma Inc. (EVOK), Catalyst Pharmaceuticals Inc. (CPRX), Neurocrine Biosciences Inc. (NBIX), and Galectin Therapeutics Inc. (GALT). As per an article on NASDAQ, the NYSE Health Care Index plummeted more than 1.3%, while shares of health care companies in the S&P 500 plunged almost 2.1% as a group. Solana Beach, California headquartered Evoke Pharma Inc.'s stock dropped 3.93%, finishing last Friday's session at $1.71 with a total trading volume of 146,014 shares."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2016 Results,2016-10-26 17:15:03 +0000,http://www.publicnow.com/view/1F4220F935B7F1C914780404C18BF3640C541B81,"[at noodls] - SAN DIEGO, Oct. 26, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2016 results after the Nasdaq market closes on Wednesday, ..."
NBIX,NBIX:UW,BBG000GJTN99,NBIX: AbbVie Presents Positive Phase 3 Data for Elagolix in Endometriosis…,2016-10-21 19:00:00 +0000,http://finance.yahoo.com/news/nbix-abbvie-presents-positive-phase-190000083.html,NBIX: AbbVie Presents Positive Phase 3 Data for Elagolix in Endometriosis…
NBIX,NBIX:UW,BBG000GJTN99,"CERU Gains Big On Nanoparticle Deal, LLY Gets FDA Nod, BABY Makes Big Strides",2016-10-20 01:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yBWOilte3bA/ceru-gains-big-on-nanoparticle-deal-lly-gets-fda-nod-baby-makes-big-strides-20161020-00031,"CERU Gains Big On Nanoparticle Deal, LLY Gets FDA Nod, BABY Makes Big Strides"
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Menstrual Pelvic Pain Associated with Endometriosis at the American Society for Reproductive Medicine Scientific Congre,2016-10-19 13:00:00 +0000,http://finance.yahoo.com/news/abbvie-announces-positive-pivotal-phase-130000828.html,"[PR Newswire] - NORTH CHICAGO, Ill., Oct. 19, 2016 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NBIX), today announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale."
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Announces Positive Pivotal Phase 3 Data On Elagolix,2016-10-19 09:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tYHJSpIy3_s/abbvie-announces-positive-pivotal-phase-3-data-on-elagolix-20161019-01101,AbbVie Announces Positive Pivotal Phase 3 Data On Elagolix
NBIX,NBIX:UW,BBG000GJTN99,Surprising Analyst 12-Month Target For FBT,2016-10-17 13:41:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cr-UILaU7EY/surprising-analyst-12-month-target-for-fbt-cm693974,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
NBIX,NBIX:UW,BBG000GJTN99,BofA: Expect upside to Merck estimates,2016-10-13 16:24:00 +0000,http://finance.yahoo.com/video/bofa-expect-upside-merck-estimates-162400174.html,BofA: Expect upside to Merck estimates
NBIX,NBIX:UW,BBG000GJTN99,"Here’s Our Take On Neurocrine Biosciences, Inc. (NBIX)’s Ingrezza",2016-10-12 19:44:59 +0000,http://www.insidermonkey.com/blog/heres-our-take-on-neurocrine-biosciences-inc-nbixs-ingrezza-480925/,"Here’s Our Take On Neurocrine Biosciences, Inc. (NBIX)’s Ingrezza"
NBIX,NBIX:UW,BBG000GJTN99,"IPCI Continues To Move Up, NBIX To Face FDA In April, Good Tidings From NYMX",2016-10-12 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9xVzYcCTNE/ipci-continues-to-move-up-nbix-to-face-fda-in-april-good-tidings-from-nymx-20161012-00026,"IPCI Continues To Move Up, NBIX To Face FDA In April, Good Tidings From NYMX"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Breaks Below 200-Day Moving Average - Notable for NBIX,2016-10-12 01:17:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MJVai-VL3ak/neurocrine-biosciences-breaks-below-200-day-moving-average-notable-for-nbix-cm692129,In trading on Tuesday shares of Neurocrine Biosciences Inc Symbol NBIX crossed below their 200 day moving average of 45 62 changing hands as low as 44 65 per share Neurocrine Biosciences Inc shares are currently trading off about 3 4 on the day The chart below shows the one
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events",2016-10-11 12:32:38 +0000,http://biz.yahoo.com/e/161011/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA,2016-10-11 11:09:07 +0000,http://www.publicnow.com/view/5C8CF62C63FD1047F000DB3A350F493895524653,"[at noodls] - SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine: FDA Accepts For Priority Review INGREZZA NDA In Tardive Dyskinesia,2016-10-11 07:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X2CIXdCAd-E/neurocrine-fda-accepts-for-priority-review-ingrezza-nda-in-tardive-dyskinesia-20161011-01263,Neurocrine: FDA Accepts For Priority Review INGREZZA NDA In Tardive Dyskinesia
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix and Research on the Economic Burden of Endometriosis at the 72nd American Society for Reproductive Medicine Scientific Congress,2016-10-06 12:00:00 +0000,http://finance.yahoo.com/news/abbvie-presents-pivotal-phase-3-120000970.html,"[PR Newswire] - NORTH CHICAGO, Ill., Oct. 6, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that new data ..."
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : October 3, 2016",2016-10-03 16:23:28 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-value-analysis-nasdaqnbix-october-3-2016/,"Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : October 3, 2016"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : September 30, 2016",2016-09-30 12:29:32 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bearish-manner-nbix-us-september-30-2016/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : September 30, 2016"
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan",2016-09-23 20:32:35 +0000,http://biz.yahoo.com/e/160923/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan"
NBIX,NBIX:UW,BBG000GJTN99,Blue Jay Capital Betting On Big Returns From These Healthcare Stocks,2016-09-22 14:52:13 +0000,http://www.insidermonkey.com/blog/blue-jay-capital-betting-on-big-returns-from-these-healthcare-stocks-475956/,Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine,2016-09-17 09:18:05 +0000,http://www.publicnow.com/view/D407BB5725F0796EB2ED5FBA53B92C4330D93720,"[at noodls] - SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name 'INGREZZA™' ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia,2016-09-17 09:18:05 +0000,http://www.publicnow.com/view/75735D4004909A0B54B71EA434523999AEA8AFCA,"[at noodls] - SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences To Participate In Morgan Stanley Conference At 11:10 AM,2016-09-13 10:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y7vbvhaTIOw/neurocrine-biosciences-to-participate-in-morgan-stanley-conference-at-1110-am-20160913-00696,Neurocrine Biosciences To Participate In Morgan Stanley Conference At 11:10 AM
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference,2016-09-07 20:05:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-morgan-stanley-200500199.html,"[PR Newswire] - SAN DIEGO, Sept. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley Healthcare Conference in New York City. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences To Participate In Baird Healthcare Conference At 11:25 AM,2016-09-07 10:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HSAjfCoaVB0/neurocrine-biosciences-to-participate-in-baird-healthcare-conference-at-1125-am-20160907-00808,Neurocrine Biosciences To Participate In Baird Healthcare Conference At 11:25 AM
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference,2016-09-01 17:00:00 +0000,http://finance.yahoo.com/news/neurocrine-biosciences-present-baird-2016-170000514.html,"[PR Newswire] - SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Baird 2016 Healthcare Conference in New York City. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine,2016-08-31 20:33:08 +0000,http://www.publicnow.com/view/04BD39A8482BE0863E8FBDD362D605C1B0C588BA,"[at noodls] - SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name 'INGREZZA™' ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine,2016-08-31 20:02:00 +0000,http://finance.yahoo.com/news/neurocrine-announces-fda-conditional-acceptance-200200026.html,"[PR Newswire] - SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name ""INGREZZA™"" for the Company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The name INGREZZA (pronounced in-GREH-zah) was developed using the FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names consistent with the goal of preventing medication errors."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia,2016-08-29 20:33:07 +0000,http://www.publicnow.com/view/3F62861ACAAED78C1E903058DBE28ED41CA50A7D,"[at noodls] - SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia,2016-08-29 20:02:00 +0000,http://finance.yahoo.com/news/neurocrine-submits-drug-application-valbenazine-200200734.html,"[PR Newswire] - SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating tardive dyskinesia. ""This is an important milestone in the development of valbenazine for the treatment of tardive dyskinesia, a serious disease for which there is no FDA approved pharmaceutical treatment,"" said Kevin C. Gorman, President and Chief Executive Officer of Neurocrine Biosciences."
NBIX,NBIX:UW,BBG000GJTN99,Appeals Court Tosses Data Speed Case Brought Against AT&T,2016-08-29 16:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Om36nCr1Ke8/appeals-court-tosses-data-speed-case-brought-against-att-20160829-00650,Appeals Court Tosses Data Speed Case Brought Against AT&T
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster,2016-08-26 14:04:05 +0000,http://marketrealist.com/2016/08/abbvie-expects-investigational-womens-health-drug-elagolix-become-blockbuster-therapy/?utm_source=yahoo&utm_medium=feed,AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster
NBIX,NBIX:UW,BBG000GJTN99,"ETF’s with exposure to Neurocrine Biosciences, Inc. : August 12, 2016",2016-08-12 18:35:23 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-neurocrine-biosciences-inc-august-12-2016/,"ETF’s with exposure to Neurocrine Biosciences, Inc. : August 12, 2016"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : August 11, 2016",2016-08-11 12:14:07 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bearish-manner-nbix-us-august-11-2016/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : August 11, 2016"
NBIX,NBIX:UW,BBG000GJTN99,NBIX: NDA for Valbenazine in Tardive Dyskinesia Set to be Filed; Data From Tourette Syndrome Trials at Year End,2016-08-04 15:30:00 +0000,http://finance.yahoo.com/news/nbix-nda-valbenazine-tardive-dyskinesia-153000002.html,NBIX: NDA for Valbenazine in Tardive Dyskinesia Set to be Filed; Data From Tourette Syndrome Trials at Year End
NBIX,NBIX:UW,BBG000GJTN99,Edited Transcript of NBIX earnings conference call or presentation 3-Aug-16 9:00pm GMT,2016-08-04 06:42:53 +0000,http://finance.yahoo.com/news/edited-transcript-nbix-earnings-conference-064253541.html,Edited Transcript of NBIX earnings conference call or presentation 3-Aug-16 9:00pm GMT
NBIX,NBIX:UW,BBG000GJTN99,"AXGN Making News, Milestone Events Lined Up For NBIX, Cesca Plays It Cool",2016-08-04 00:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AMgKJTxU77c/axgn-making-news-milestone-events-lined-up-for-nbix-cesca-plays-it-cool-20160804-00007,"AXGN Making News, Milestone Events Lined Up For NBIX, Cesca Plays It Cool"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 2Q loss,2016-08-03 21:55:54 +0000,http://sg.finance.yahoo.com/news/neurocrine-reports-2q-loss-215554006.html,Neurocrine reports 2Q loss
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports Second Quarter 2016 Results,2016-08-03 20:22:19 +0000,http://www.publicnow.com/view/122E83659365E708B3638B16B6F1D25A6CCBBE76,"[at noodls] - SAN DIEGO, Aug. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2016. For the second quarter of 2016, the Company ..."
NBIX,NBIX:UW,BBG000GJTN99,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an",2016-08-03 20:16:29 +0000,http://biz.yahoo.com/e/160803/nbix8-k.html,"NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Q2 16 Earnings Conference Call At 5:00 PM ET,2016-08-03 15:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QeoJRHOxFuc/neurocrine-biosciences-q2-16-earnings-conference-call-at-500-pm-et-20160803-00971,Neurocrine Biosciences Q2 16 Earnings Conference Call At 5:00 PM ET
NBIX,NBIX:UW,BBG000GJTN99,Q2 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close,2016-08-03 11:07:04 +0000,http://biz.yahoo.com/research/earncal/20160803.html?t=nbix,Q2 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome,2016-07-28 20:28:05 +0000,http://www.publicnow.com/view/D5565D49A35EF4F421D34515A261056B596336A6,"[at noodls] - SAN DIEGO, July 28, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results,2016-07-27 17:38:01 +0000,http://www.publicnow.com/view/AE9ECF075A1387FF593303E12966A011669F0CC8,"[at noodls] - SAN DIEGO, July 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, ..."
NBIX,NBIX:UW,BBG000GJTN99,"Noteworthy Tuesday Option Activity: WFT, LDOS, NBIX",2016-07-26 21:21:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8F69Z2R3nwU/noteworthy-tuesday-option-activity-wft-ldos-nbix-cm655166,"Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Weatherford International plc (Symbol WFT), where a total volume of 59,286 contracts has been traded thus far today, a contract volume"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : July 20, 2016",2016-07-20 17:11:19 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-value-analysis-nasdaqnbix-july-20-2016/,"Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : July 20, 2016"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 19, 2016",2016-07-19 12:15:48 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-july-19-2016/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 19, 2016"
NBIX,NBIX:UW,BBG000GJTN99,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 7, 2016",2016-07-07 12:13:02 +0000,http://www.capitalcube.com/blog/index.php/neurocrine-biosciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nbix-us-july-7-2016/,"Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 7, 2016"
NBIX,NBIX:UW,BBG000GJTN99,Inside Neurocrine Biosciences’ Focus on Tourette Syndrome,2016-06-30 15:07:43 +0000,http://marketrealist.com/2016/06/neurocrine-biosciences-focuses-underserved-tourette-syndrome-market/?utm_source=yahoo&utm_medium=feed,Inside Neurocrine Biosciences’ Focus on Tourette Syndrome
NBIX,NBIX:UW,BBG000GJTN99,Positive Top-Line Data May Help Secure FDA Approval for Valbenazine,2016-06-30 13:07:43 +0000,http://marketrealist.com/2016/06/positive-top-line-data-kinect-3-study-may-help-securing-fda-approval-valbenazine/?utm_source=yahoo&utm_medium=feed,Positive Top-Line Data May Help Secure FDA Approval for Valbenazine
NBIX,NBIX:UW,BBG000GJTN99,Inside Neurocrine Biosciences’ Analyst Recommendations in 2016,2016-06-29 21:09:09 +0000,http://marketrealist.com/2016/06/inside-neurocrine-biosciences-analyst-recommendations-2016/?utm_source=yahoo&utm_medium=feed,Inside Neurocrine Biosciences’ Analyst Recommendations in 2016
NBIX,NBIX:UW,BBG000GJTN99,3 Biotech Stocks to Buy in July,2016-06-25 21:26:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a2wY7SVDqB8/3-biotech-stocks-to-buy-in-july-cm640808,Image source  Getty Images.  It's been a rough year to be a biotech investor. The market cap weighted iShares Nasdaq Biotechnology ETF (NASDAQ  IBB) is down about 25% so far this year.
NBIX,NBIX:UW,BBG000GJTN99,3 Biotech Stocks to Buy in July,2016-06-25 19:21:00 +0000,http://www.fool.com/investing/2016/06/25/3-biotech-stocks-to-buy-in-july.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks to Buy in July
NBIX,NBIX:UW,BBG000GJTN99,"Commit To Purchase Neurocrine Biosciences At $39, Earn 18.8% Annualized Using Options",2016-06-23 17:01:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2-WjcK7e-NE/commit-to-purchase-neurocrine-biosciences-at-39-earn-188-annualized-using-options-cm639659,"Investors eyeing a purchase of Neurocrine Biosciences, Inc. (Symbol NBIX) stock, but cautious about paying the going market price of $43.72 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Breaks Below 200-Day Moving Average - Notable for NBIX,2016-06-14 18:09:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MWTVJxwjY-Y/neurocrine-biosciences-breaks-below-200-day-moving-average-notable-for-nbix-cm635352,"In trading on Tuesday, shares of Neurocrine Biosciences, Inc. (Symbol NBIX) crossed below their 200 day moving average of $45.94, changing hands as low as $45.72 per share. Neurocrine Biosciences, Inc. shares are currently trading off about 1.2% on"
NBIX,NBIX:UW,BBG000GJTN99,FBT's Underlying Holdings Could Mean 28% Gain Potential,2016-06-13 12:19:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aq8cqW7whwM/fbts-underlying-holdings-could-mean-28-gain-potential-cm634342,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
NBIX,NBIX:UW,BBG000GJTN99,Insiders See Huge Upside In These Biotechs,2016-06-12 21:25:54 +0000,http://finance.yahoo.com/tumblr/blog-insiders-see-huge-upside-in-these-biotechs-212600236.html,Insiders See Huge Upside In These Biotechs
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences To Present At Jefferies Conference At 10:30 AM ET,2016-06-08 09:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w4dxbKd2zs4/neurocrine-biosciences-to-present-at-jefferies-conference-at-1030-am-et-20160608-00532,Neurocrine Biosciences To Present At Jefferies Conference At 10:30 AM ET
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference,2016-06-02 20:05:02 +0000,http://www.publicnow.com/view/17CA205D47FAF635B596E93062AD1314134E8127,"[at noodls] - SAN DIEGO, June 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 ..."
NBIX,NBIX:UW,BBG000GJTN99,5 stocks to watch,2016-06-01 18:18:00 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=417D0B4E-C89F-4E45-A60A-985B0F2FF255&siteid=yhoof2,5 stocks to watch
NBIX,NBIX:UW,BBG000GJTN99,Stocks Continue To Turn In Lackluster Performance - U.S. Commentary,2016-05-31 12:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tb0dKJCAM90/stocks-continue-to-turn-in-lackluster-performance--us-commentary-20160531-00810,Stocks Continue To Turn In Lackluster Performance - U.S. Commentary
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors,2016-05-20 13:13:09 +0000,http://www.publicnow.com/view/C37B8591405D00F7F9B1DF39044A8A0C34436CF1,"[at noodls] - SAN DIEGO, May 20, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective ..."
NBIX,NBIX:UW,BBG000GJTN99,"XBI, MDVN, NBIX, ALKS: ETF Inflow Alert",2016-05-17 16:49:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5yEuDLaVdr0/xbi-mdvn-nbix-alks-etf-inflow-alert-cm622292,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $60.5 million dollar inflow"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIX,2016-05-16 17:48:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PghyUhAFoqg/neurocrine-biosciences-breaks-above-200-day-moving-average-bullish-for-nbix-cm621667,"In trading on Monday, shares of Neurocrine Biosciences, Inc. (Symbol NBIX) crossed above their 200 day moving average of $45.90, changing hands as high as $46.07 per share. Neurocrine Biosciences, Inc. shares are currently trading up about 5.1% on"
NBIX,NBIX:UW,BBG000GJTN99,Sum Up The Pieces: JKH Could Be Worth $172,2016-05-12 15:28:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QiiZ9zDDPho/sum-up-the-pieces-jkh-could-be-worth-172-cm620128,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference,2016-05-10 11:08:10 +0000,http://www.publicnow.com/view/8C3FF771EB088C5EFDEDD7B88BB1CCD342CF38B2,"[at noodls] - SAN DIEGO, May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta,2016-05-06 19:34:07 +0000,http://www.publicnow.com/view/606482D6E03D31DF000BE909A5EE9771DA46CA88,"[at noodls] - SAN DIEGO, May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports First Quarter 2016 Results,2016-05-06 13:14:09 +0000,http://www.publicnow.com/view/77307D6115EAE38ED9B3EB24F324C00890378586,"[at noodls] - SAN DIEGO, May 5, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, the Company ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 1Q loss,2016-05-05 22:22:36 +0000,http://sg.finance.yahoo.com/news/neurocrine-reports-1q-loss-222236881.html,Neurocrine reports 1Q loss
NBIX,NBIX:UW,BBG000GJTN99,SPDR S&P Biotech ETF Experiences Big Outflow,2016-05-02 16:43:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jgVmfzHFlTo/spdr-sp-biotech-etf-experiences-big-outflow-cm614635,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $43.1 million dollar outflow"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results,2016-04-29 19:08:19 +0000,http://www.publicnow.com/view/E4D904115E631B133AF573B6D9DB2C12CBD00B91,"[at noodls] - SAN DIEGO, April 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference,2016-04-27 19:10:30 +0000,http://www.publicnow.com/view/3CD5C74C0CAE1A53E7A2384CF6DD59ED7E1DB229,"[at noodls] - SAN DIEGO, April 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche ..."
NBIX,NBIX:UW,BBG000GJTN99,"Noteworthy ETF Outflows: XBI, MDVN, NBIX, ICPT",2016-04-22 08:22:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hckH8lZwBSE/noteworthy-etf-outflows-xbi-mdvn-nbix-icpt-cm609601,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $183.0 million dollar outflow"
NBIX,NBIX:UW,BBG000GJTN99,SPDR S&P Biotech ETF Experiences Big Inflow,2016-04-13 16:07:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6LNy0EnxnnY/spdr-sp-biotech-etf-experiences-big-inflow-cm605781,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $76.9 million dollar inflow"
NBIX,NBIX:UW,BBG000GJTN99,Implied FBT Analyst Target Price: $122,2016-04-11 14:03:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vubpOFm-6r4/implied-fbt-analyst-target-price-122-cm604318,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
NBIX,NBIX:UW,BBG000GJTN99,NBIX Crosses Above Key Moving Average Level,2016-04-06 21:58:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fk24zkpdHHg/nbix-crosses-above-key-moving-average-level-cm602740,"In trading on Wednesday, shares of Neurocrine Biosciences, Inc. (Symbol NBIX) crossed above their 200 day moving average of $46.38, changing hands as high as $46.57 per share. Neurocrine Biosciences, Inc. shares are currently trading up about 8.2% on"
NBIX,NBIX:UW,BBG000GJTN99,Interesting NBIX Put And Call Options For November 18th,2016-03-22 17:14:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/24A7VEp2GPw/interesting-nbix-put-and-call-options-for-november-18th-cm596441,"Investors in Neurocrine Biosciences, Inc. (Symbol NBIX) saw new options become available this week, for the November 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time"
NBIX,NBIX:UW,BBG000GJTN99,Interesting NBIX Put And Call Options For April 15th,2016-02-25 16:25:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HG7zpHW6R9I/interesting-nbix-put-and-call-options-for-april-15th-cm584792,"Investors in Neurocrine Biosciences, Inc. (Symbol NBIX) saw new options become available this week, for the April 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the NBIX options chain for the new"
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 4Q loss,2016-02-11 22:31:39 +0000,http://sg.finance.yahoo.com/news/neurocrine-reports-4q-loss-223139805.html,Neurocrine reports 4Q loss
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference,2016-01-04 19:19:28 +0000,http://www.noodls.com/view/46258AF148F191031312A09BEEF5B467BCB970BB,"[at noodls] - , /PRNewswire/ -- (Nasdaq: NBIX) announced today that , President and Chief Executive Officer of , will be presenting at the 34 Annual in San Francisco. The live presentation takes place on at (). The ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference,2015-11-25 18:25:22 +0000,http://www.noodls.com/view/661EE5BCA79ED980428805293F17B5EB05677B01,"[at noodls] - SAN DIEGO, Nov. 25, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 27th Annual ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences to Present at the Jefferies Autumn 2015 Global Healthcare Conference,2015-11-11 19:36:07 +0000,http://www.noodls.com/view/24931ADD9B3CFEC9A4CCF485D7578C3BC32AC8B3,"[at noodls] - SAN DIEGO, Nov. 11, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Expansion of its Clinical Pipeline,2015-11-04 13:17:16 +0000,http://www.noodls.com/view/A5F653A746D221545DE429E37E5E5815FF7F9B79,"[at noodls] - SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that the Company's ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine reports 3Q loss,2015-10-29 20:47:53 +0000,http://sg.finance.yahoo.com/news/neurocrine-reports-3q-loss-204753778.html,Neurocrine reports 3Q loss
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Reports Third Quarter 2015 Results,2015-10-29 20:18:07 +0000,http://www.noodls.com/view/2771AECCCB6E1D1B195DD7E9C0B23C25CD4769AE,[at noodls] - Neurocrine Biosciences Reports Third Quarter 2015 Results
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results,2015-10-22 17:29:09 +0000,http://www.noodls.com/view/655904F8AC147E674BEE5A73C1CF642BB2A0FEA3,"[at noodls] - SAN DIEGO, Oct. 22, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2015 financial results after the Nasdaq market closes ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome,2015-10-20 13:02:03 +0000,http://www.noodls.com/view/D8C79E78AAC10BF49DF170F1BCCD3E289CC452C7,"[at noodls] - SAN DIEGO, Oct. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has expanded the clinical efforts for NBI-98854 (Valbenazine), a highly selective small molecule ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia,2015-10-08 10:44:08 +0000,http://www.noodls.com/view/0A3F5D3E202E3D37C495EAF747F8929557ACEF80,"[at noodls] - SAN DIEGO, Oct. 8, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors,2015-09-30 20:38:02 +0000,http://www.noodls.com/view/7DB150917AF3B73D8AF3C36999104C0E6447AB35,"[at noodls] - SAN DIEGO, Sept. 30, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has appointed George J. Morrow to its Board of Directors. Mr. Morrow has over three decades ..."
NBIX,NBIX:UW,BBG000GJTN99,AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids,2015-09-16 16:49:06 +0000,http://www.noodls.com/view/3EFF089BF307627DA1248BB05E640C380626A61E,"[at noodls] - NORTH CHICAGO, Ill. , Sept. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the completion of a Phase 2b clinical trial evaluating ..."
NBIX,NBIX:UW,BBG000GJTN99,Neurocrine meets 3Q profit forecasts,2014-11-03 23:00:43 +0000,http://sg.finance.yahoo.com/news/neurocrine-meets-3q-profit-forecasts-230043437--finance.html,Neurocrine meets 3Q profit forecasts
